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Riassunto
L'obiettivo di questo lavoro di tesi era determinare la struttura tridimensionale di tre 
proteine umane, Heat shock protein 60 (HSP60), Activation-induced cytidine deaminase 
(AICDA)  e  Cholesterol  7-alpha-monooxygenase  (CYP7A1),  attraverso  la  tecnica  di 
diffrazione di raggi X.
La  chaperonina  umana  HSP60  è  una  proteina  mitocondriale,  espressa  in  maniera 
costitutiva. La proteina è stata espressa in E. coli e purificata tramite cromatografia di 
affinità  immobilizzata  dello  ione  metallo,  utilizzando  un  tag  di  sei  istidine  inserito 
all'estremità  N-terminale  della  proteina,  e  tramite  cromatografia  a  esclusione 
molecolare. Le prove di cristallizzazione non danno risultati positivi, probabilmente per 
problemi di eterogeneità della proteina.
La  AICDA umana  è  una  citidina  deaminasi,  la  quale  è  selettivamente  espressa  nei 
linfociti  B  e  svolge  un  ruolo  cruciale  nell'ipermutazione  somatica  e  nella 
ricombinazione  per  scambio  di  classe degli  anticorpi.  L'espressione della  proteina  è 
stata  tentata  in  E. coli con differenti  vettori  ed è  stata  ottenuta con successo con il 
plasmide pGEX-4T-1, che permette di esprimere la GST all'estremità N terminale della 
proteina oggetto di studio; sfortunatamente, il protocollo di purificazione non è stato 
efficace.
La CYP7A1 è un enzima microsomale che catalizza la conversione del colesterolo a 7α-
idrossicolesterolo,  la  prima  reazione  della  sintesi  degli  acidi  biliari,  e  questa  è  la 
reazione limitante la velocità della via metabolica; la proteina è espressa solamente nel 
fegato. L'espressione della proteina umana CYP7A1 in  E. coli è stata difficoltosa e, 
sebbene siano stati  testati  differenti  vettori,  non è  stato  ottenuto  un  buon livello  di 
espressione della proteina.  Per superare questi  problemi,  la CYP7A1 di pesce zebra 
(Danio rerio) è stata espressa in E. coli, ma senza apprezzabili miglioramenti.
Un'altra  parte  della  mia  tesi  ha  riguardato  la  determinazione  della  struttura 
tridimensionale della Methionine aminopeptidase 1 umana con due differenti inibitori. 
La proteina catalizza l'eliminazione della metionina N-terminale dalle proteine nascenti. 
Inibitori contro questa proteina sono di grande interesse medico grazie al loro potenziale 
impiego come farmaci antitumorali.
Questa parte di tesi è stata svolta presso il laboratorio del Dr. L. Mario Amzel sotto la 
6
supervisione della Dr. Sandra B. Gabelli - Department of Biophysics and Biophysical 
Chemistry, Johns Hopkins University, School of Medicine (Baltimore, USA).
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Abstract
The aim of this thesis work was to determine the three-dimensional structure of three 
human proteins, Heat shock protein 60 (HSP60), Activation-induced cytidine deaminase 
(AICDA) and Cholesterol 7-alpha-monooxygenase (CYP7A1), by X-ray diffraction of 
single crystals.
The human chaperonine HSP60 is a mitochondrial protein, expressed in a constitutive 
manner. The protein was expressed in  E. coli and purified by immobilized metal ion 
affinity chromatography, using a histidine tag fused to the N-terminus of the protein, 
and by size exclusion chromatography. The crystallization trials do not give positive 
results, probably due to protein heterogeneity problems.
Human  AICDA  is  a  cytidine  deaminase,  which  is  selectively  expressed  in  B 
lymphocytes  and  plays  a  crucial  role  in  antibody somatic  hypermutation  and  class 
switch recombination. Protein expression was attempted in E. coli with different vectors 
and was successfully achieved with the pGEX-4T-1 plasmid, that allows to express GST 
at the N-terminus of the target protein; unfortunately, the purification protocol was not 
effective.
CYP7A1 is a microsomal enzyme that catalyzes the conversion of cholesterol to 7α-
hydroxycholesterol, the first reaction of bile acid synthesis and the rate-limiting step of 
the metabolic pathway; the protein is expressed only in the liver.  The expression of 
human CYP7A1 in E. coli was troublesome and, although different vectors were tested, 
a  good  level  of  protein  expression  was  not  obtained.  In  order  to  overcome  these 
problems, zebrafish (Danio rerio) CYP7A1 was expressed in  E. coli, but without any 
substantial improvement.
Another part of this thesis work concerned the determination of the three-dimensional 
structure of the human Methionine aminopeptidase 1 with two different inhibitors. The 
protein  catalyzes  the  removal  of  the  N-terminal  methionine  from nascent  proteins. 
Inhibitors against this protein are of great medical interest because of their potential 
employment as anticancer drugs.
This part  of the thesis  was performed at Dr.  L.  Mario Amzel's  laboratory under the 
direct supervision of Dr. Sandra B. Gabelli - Department of Biophysics and Biophysical 
Chemistry, Johns Hopkins University, School of Medicine (Baltimore, USA).
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Abbreviations
HSP: Heat shock protein
AICDA: Activation-induced cytidine deaminase
CYP7A1: Cholesterol 7-alpha-monooxygenase
MetAP: Methionine aminopeptidase
LB: Luria-Bertani
IPTG: isopropyl β-D-1-thiogalactopyranoside
IMAC: Immobilized Metal Ion Affinity Chromatography
PMSF: phenylmethanesulfonyl fluoride
PEG: polyethylene glycol
EDTA: ethylenediaminetetraacetic acid
Ig: immunoglobulin
SHM: somatic hypermutation
CSR: class switch recombination
dsDNA: double strand DNA
ssDNA: single strand DNA
GST: Glutathione-S-transferase
TB: Terrific Broth
DTT: dithiothreitol
UDCA: ursodeoxycholic acid
CA: cholic acid
CDCA: chenodeoxycholic acid
CYP8B1: Sterol 12α-hydroxylase
CYP27A1: Sterol 27-hydroxylase
FXR: Farnesoid nuclear receptor
RXR: Retinoid X receptor
LXR: Liver X receptor
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1. Heat shock protein 60
1.1 Introduction
1.1.1 Heat Shock Proteins
Many proteins can fold spontaneously in vitro to their native state under appropriate 
conditions. Nevertheless, inside a cell,  during the protein folding process, the highly 
crowded  macromolecular  environment  favours  protein  misfolding  and  aggregation; 
aggregation is a disordered association of polypeptide chains devoid of any biological 
activity.
A group of proteins, known as molecular chaperones, counteracts in vivo the tendency 
of non-native proteins to misfold or aggregate. These proteins are essential for protein 
folding to occur with high efficiency.
Heat Shock Proteins (HSP) act as molecular chaperones during both de novo protein 
synthesis  and  under  conditions  of  cellular  stress  that  may  lead  to  unfolding  and 
aggregation of preexisting proteins. Under physiological conditions, HSP are involved 
in  mediating  protein  folding,  protein  assembly  into  oligomeric  structures,  protein 
transport, refolding of misfolded proteins and proteosome degradation. In addition, HSP 
are implicated in gene expression regulation, DNA replication, signal transduction, cell 
differentiation, apoptosis, cellular senescence and carcinogenesis [1].
Moreover,  HSP can  be  induced  in  response  to  cellular  stress  such  as  changes  in 
temperature, the presence of free oxygen radicals, heavy metals, ethanol, amino acid 
analogs, viral and bacterial infections, and ischaemia; this process is referred to as heat 
shock response [2]. While expression of some HSP is strictly inducible by stress, other 
HSP proteins are constitutively expressed at normal temperature and are only slightly 
induced by heat shock.
HSP  are  present  in  all  cellular  compartments  (cytosol,  endoplasmic  reticulum, 
mitochondria and nucleus) and they are generally considered as long half-life proteins.
According  to  their  molecular  weight  measured  in  kDa,  HSP can  be  divided  into 
different  families:  small  HSP,  HSP60,  HSP70  and  HSP90 [3].  HSP from the  same 
family often show a significant amount of sequence homology and are structurally and 
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functionally correlated, while no such homology has been found between chaperones 
from different families.
The small heat shock proteins (sHSP) have a molecular weight ranging from 25 to 40 
kDa;  they  are  ATP-dependent  and  are  thought  to  form oligomers  through  their  C-
terminal  core  domain.  One  sHSP complex  can  bind  several  substrate  proteins;  the 
subsequent refolding is performed by a different chaperone [3].
The members of the HSP60 family, also called chaperonins, are highly expressed in a 
constitutive manner and are only moderately induced by stress.
They act by forming a double ring complex with a central cavity enclosed in each ring.
Chaperonines  can  be  divided  into  two  different  groups,  which  share  a  similar 
architecture but are distantly related in primary sequence. Group I has been found in 
bacteria, mitochondria and chloroplasts, while group II is present in Archea and in the 
cytosol of eukaryotes.  Members of group I require HSP10 as a cofactor, which was 
suggested to serve as cavity lid, instead Group II chaperonins do not require HSP10.
The best characterized group I chaperonine is GroEL from Escherichia coli; its cofactor 
is GroES. The GroEL complex is constituted by two rings, each of them formed by 
seven GroEL molecules. 
Figure 1.1: Three-dimensional structure of GroE chaperone from E. coli, determined by X-ray 
diffraction. Side view of GroE complex (left); distal GroEL ring is shown in grey, the seven subunits of 
the proximal GroEL are shown in shades of green, GroES is bound to the proximal ring and is shown in 
red. Cross-section of the GroE complex (right) [4].
Each subunit presents an equatorial ATP-binding domain, a hinge domain and an apical 
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substrate-binding domain. After binding of the substrate to one of the two rings, seven 
ATP molecules and GroES bind to that ring, thus determining the encapsulation of the 
substrate.  As a result of GroES binding, GroEL undergoes a conformational change, 
with an enlargement of the cavity, providing an adequate environment for the substrate 
protein to fold without aggregating. ATP hydrolysis and ATP binding to the other ring 
determine GroES and protein substrate release. Many folding cycles are thought to be 
required for the substrate correct folding.
The HSP70 family represents the most highly conserved molecular chaperones and its 
members have been found in bacteria, Archea, eukaryotic cytosol, eukaryotic nucleus, 
mitochondria and chloroplasts.
The  expression  of  some  members  of  this  family  is  strongly  induced  under  stress 
conditions.
HSP70 are involved in both newly synthesized protein folding and in prevention of 
protein aggregation in several post-translational processes, such as protein degradation, 
protein targeting and membrane translocation. HSP70 chaperones act through an ATP-
regulated cycle of substrate binding and release. The members of this family require 
cooperation  with  different  cofactors  to  modulate  their  ATPase  activity  and for  their 
correct targeting to specific cellular structures [3].
The HSP90 family plays an important role in conformational protein regulation and cell 
signaling. These chaperones are thought to form homodimers.
Substrate loading was suggested to be mediated by the protein p60/Hop, which interacts 
with both HSP70 and HSP90; after loading, HSP90 undergoes regulated cycles of ATP 
binding and hydrolysis and eventually releases the native protein.
Under  stress  conditions,  this  chaperone  acts  as  a  general  storage  compartment  for 
unfolded proteins, which can subsequently be refolded by a different chaperone.
HSP90  is  associated  with  a  multi-chaperone  machinery,  which,  depending  on  the 
substrate  protein  bound,  includes  several  cofactors;  some of  these  cofactors  present 
enzymatic activity, such as peptidylprolyl isomerases and serine/threonine phosphatase 
5. Other cofactors are located at specific cellular structures, where they act as docking 
partners for the chaperone; for example, one of these cofactors, Tom70, is located in the 
13
outer mitochondrial membrane [3].
1.1.2 Human HSP60
The human chaperonine HSP60 is a mitochondrial protein; the HSP60 precursor has an 
N-terminal mitochondrial targeting sequence, which is cleaved during its import into the 
organelle [5]. But this protein has also been detected in other loci, such as cytosol, cell 
surface,  extracellular  space  and  circulation.  HSP60  was  detected  on  the  surface  of 
normal and tumor cells. An increased level of the protein on the cell surface is thought 
to  be  a  danger  signal  for  the  immune  system  cells,  able  to  induce  activation  and 
maturation of dendritic cells  and generation of an antitumor T-cell  response.  HSP60 
located in extracellular space is thought to be able to interact with several cell surface 
receptors, such as CD14, CD40 and Toll-like receptors; moreover, HSP60 can cause 
pro- and anti-inflammatory effects and can bind peptides, for example tumor derived 
peptide antigens,  and present  them to immune system cells.  Additionally,  HSP60 is 
present in the blood stream and can be detected in plasma of healthy subjects [6].
Innate immune system stimulation by HSP60
Besides  being  involved  in  protein  folding,  HSP60  exhibits  immunoregulatory 
properties, i. e. it is thought to be a potent regulator of innate immune cell activity able 
to induce pro-inflammatory processes.
HSP60  and  also  HSP70  are  present  in  detectable  amounts  in  blood  of  healthy 
individuals; moreover, HSP serum levels were observed to be highly increased under 
several pathological conditions, such as hypertension, atherosclerosis and renal vascular 
diseases.
HSP60 is a potent activator of cells of the innate immune system, such as macrophages, 
dendritic  cells  and  endothelial  cells.  Dendritic  cells  incubated  with  HSP60  show  a 
significant  raise in  release of tumor necrosis  factor α,  interleukin-6 and chemokines 
RANTES and MIP-2. In innate immune cells, HSP60 stimulates the formation and the 
release of the pro-inflammatory mediators IL-1β, MCP-1, MIP-1α and the short-lived 
radical nitric oxide. In addition, production of the T helper 1 cell promoting cytokines 
IL-12 and IL-15 is increased [7].
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Different HSP60 epitopes are responsible for binding and activation of innate immune 
cells. Using the macrophage line J774a.1, an epitope in the C-terminal region (481-500 
aa) was identified [8]. With a different macrophage cell line, three completely different 
epitopes of HSP60 (241-260 aa, 391-410 aa and 461-480 aa) were found [9]. Therefore 
it was suggested that different regions of HSP60 are responsible for the interaction with 
different innate immune cell types.
Besides, a completely different epitope (354-365 aa) was proved to be responsible for 
the binding of HSP60 to LPS (lipopolysaccharide),  a major component of the outer 
membrane of Gram-negative bacteria, which can strongly elicit immune response; the 
central motif of this epitope (LKGK) is thought to be crucial for the binding, as it is 
present  also  in  factor  C  from  Limulus  polyphemus,  another  protein  able  to  bind 
efficiently LPS. Interestingly, this motif is conserved in all mammalian HSP60, but not 
in prokaryotic ones [7].
Deficiency of HSP60
Since  HSP60 is  essential  for  cell  survival,  there are  only few instances  of  diseases 
caused by lack of this protein.
Hereditary  spastic  paraplegia  SPG13  is  a  genetic  disorder  caused  by  the  missense 
mutation  V72I;  the  mutated  residue  is  a  conserved  valine  located  in  the  equatorial 
domain of HSP60.
This pathology is characterized by progressive weakness and spasticity of the lower 
limbs, caused by degeneration of the distal ends of long axons in the spinal cord. It is 
not clear why the cells affected by HSP60 dysfunction are the motoneurons of the lower 
limbs;  one possible  explanation is  that  the mutation affects  the correct  folding of a 
limited set of protein substrates which play an important role in this cellular type.
Since this is an autosomal dominant pathology, it was hypothesized that, when mutated 
HSP60 subunits are incorporated into the two-ring complex, this complex is not fully 
active [3, 10].
A patient was found affected by a systemic mitochondrial encephalomyopathy, which 
was caused by multiple deficiency in mitochondrial enzymes; the lower level of HSP60 
detected in the patient was hypothesized to be the cause of the disease [11].
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In  a  patient  with  congenital  lactic  acidaemia,  a  substantially  decreased  amount  of 
HSP60 in cultured fibroblasts was reported; the disease was caused by insufficiency of 
the mitochondrial  enzymes involved in cellular  respiration,  probably due to the low 
level of HSP60 [12].
Involvement of HSP60 in autoimmune diseases
The  amino  acid  sequence  of  the  HSP60  family  is  highly  conserved  throughout 
evolution. As a consequence, human and bacterial proteins share a sequence homology 
of about 50%; for example, human and  E. coli HSP60 proteins share 52% sequence 
identity and 67% sequence similarity. It was suggested that immune response elicited in 
the human body against bacterial  HSP60 may result  in crossreactivity to the human 
HSP60, thus determining an autoimmune reaction [13].
For example, autoimmunity to HSP60 may be involved in some cases of infertility and 
embryo  loss,  caused by damage  or  occlusion  of  the  fallopian  tubes,  resulting  after 
chlamydial infections. Human cells chronically infected by Chlamydia trachomatis, an 
obligate  intracellular  parasite,  synthesize  high  levels  of  chlamydial  HSP60;  indeed, 
during  an  infection,  this  pathogen  greatly  enhances  HSP synthesis  as  a  protective 
response  against  stressful  environmental  conditions,  such  as  nutrient  deprivation, 
changes in pH and exposure to oxygen radicals.
Human HSP60 is highly expressed during the pre-implantation and implantation stages 
of  pregnancy  by  the  maternal  decidua  and  the  embryo.  Lymphocytes  previously 
sensitized  to  chlamidyal  HSP60 could  be  reactivated  and  release  inflammatory  and 
cytotoxyc  mediators.  As  a  result,  immune  regulatory  mechanisms  required  for 
implantation  and  maintenance  of  the  embryo  may  be  perturbed,  with  deleterious 
consequences to embryo survival [2, 13].
Moreover,  cross-reactions  of  antibodies  and T cells  against  HSP60 of microbes  and 
human beings may play a role in the development of atheroscerosis.
This pathology is a multifactorial disease, characterized by accumulation of lipids in the 
blood vessel wall, mononuclear cell infiltration and smooth muscle cell proliferation. 
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Inflammatory and immune mechanisms were suggested to be one of the first processes 
in the development of atherosclerosis, because the early stages of the pathology are 
characterized by a relative paucity of lipids and an abundance of inflammatory cells, 
such as activated T lymphocytes, mast cells and macrophages, and immunoglobulins.
Most of known risk factors for this disease, such as oxidized low-density lipoprotein, 
hypertension,  infections  and  oxidative  stress,  determine  an  increase  in  HSP60 
expression levels in endothelial cells, smooth muscle cells and macrophages, which are 
the main cellular constituents of atherosclerotic plaques. 
Within atherosclerotic plaques,  the presence of T lymphocytes responding to human 
HSP60 has been reported; moreover, the level of autoantibodies directed against HSP60 
is increased in patients with atherosclerosis.
It was hypothesized that the immune reaction directed against microbial HSP60, owing 
to the high sequence identity of this protein across species, may be misdirected towards 
human  HSP60  which  is  expressed  in  the  stressed  cells  of  the  blood  vessels,  thus 
contributing to initiation and propagation of atherosclerosis [14].
Prion diseases and HSP60
Certain  neurodegenerative  diseases,  including  bovine  spongiform encephalopathy in 
cattle  and  Creutzfeldt-Jakob  disease  in  humans,  are  mediated  by prions.  The  prion 
particle consists of PrPSc, a posttranslationally modified isoform of the host – encoded 
prion protein (PrP).
The interaction between human HSP60 and PrP was reported in a yeast two hybrid 
screen [15]. Additionally, it was shown that E. coli HSP60 homologous can convert PrP 
to  the  pathogenic  isoform  PrPSc in  vitro  [16].  Nevertheless,  all  these  results  were 
obtained only in vitro and HSP60 and PrP are not known to occur in the same cellular 
compartment.
Involvement of HSP60 in apoptosis and cancer
HSP60 was suggested to be involved in processes of apoptosis and tumorigenesis.
The pro-caspase-3,  whose activation is  regarded as a  central  event  in  the execution 
phase of apoptosis, was found to be present in the mitochondrial fraction of Jurkat T 
cells in a complex with HSP60 and HSP10. Induction of apoptosis with staurosporine 
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caused the activation of the pro-caspase-3 and its dissociation from the HSP60-HSP10 
complex; moreover, the simultaneous release of HSP from mitochondria was observed, 
along with the release of other mitochondrial transmembrane space proteins, such as 
cytochrome  c.  Furthermore,  HSP60  and  HSP10  were  found  to  associate  with  pro-
caspase-3 and to accelerate its activation in vitro. Accordingly, it was suggested that the 
release of HSP60 from mitochondria may accelerate caspase activation in the cytoplasm 
of intact cells and thus HSP60 may play a pro-apoptotic role [17].
On the other hand, an anti-apoptotic role of cytosolic HSP60 was proposed in cardiac 
myocytes, a cell type that has abundant mitochondria; HSP60 was shown to interact 
with  the  pro-apoptotic  Bax  and  Bak  proteins,  preventing  the  apoptotic  process.  A 
reduction in HSP60 level, obtained by the antisense technique, caused apoptosis and 
was  associated  with  an  increase  in  Bax  protein  and  a  decrease  in  BCL-2  protein. 
Additionally,  it  was  demonstrated  that  cytosolic  HSP60  forms  a  macromolecular 
complex with Bax and Bak in vitro; it was suggested that the complex formation with 
HSP60 may block the ability of Bax and Bak to effect apoptosis in vivo.  Finally,  a 
reduction in cytosolic HSP60 was associated with an increase in the number of Bax 
protein present in the mitochondrial fraction. Since Bax alone is sufficient to induce 
cytochrome c release and consequently apoptosis, the interaction between HSP60 and 
Bax was suggested to play a critical role in preventing apoptosis [1, 18].
The presence and levels of HSP60 have been examined in a variety of tumors from 
different tissues; the results obtained indicate that detection and quantification of HSP60 
may be useful for histopathological diagnosis and for prognosis [6].
For  example,  in  an  immunohistochemical  study of  bladder  carcinoma,  HSP60  was 
found at low levels or absent in tumor specimens, while the protein was expressed in 
normal urothelium. The authors suggested that HSP60 may be a very useful marker for 
patients  with  superficial  bladder  carcinoma;  in  particular,  low  HSP60  levels  are 
correlated  with  unfavourable  prognosis  after  local  treatment  of  superficial  bladder 
carcinoma [19].
While HSP60 was scarce or absent in normal prostatic tissue, increased levels of the 
protein were reported in prostatic carcinogenesis; accordingly, HSP60 was suggested to 
be a marker for prostate malignancy [20].
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1.2 Materials and Methods
1.2.1 The human HSP60 clone
The plasmid containing the full-length cDNA clone (IMAGE ID 2821157) of human 
HSP60  was  purchased  from  RZPD  (Deutsches  Ressourcenzentrum  fur 
Genomforschung). E. coli cells harbouring the plasmid vector pOTB7 were grown in 3 
ml of Luria-Bertani (LB) medium containing 50  μg/ml  chloramphenicol overnight at 
37ºC.
Cells were harvested by centrifugation and the plasmid vector was purified using the 
GenElute™ Plasmid Miniprep kit (Sigma-Aldrich®).
1.2.2 Subcloning of HSP60 gene into pET15b plasmid
The  coding  sequence  of  the  protein  without  the  N-terminal  27  amino  acids, 
corresponding to the mitochondrial targeting signal, was amplified by a PCR reaction 
using the following primers and parameters.
Primer forward:
5'-GGTGGTCATATGGCCAAAGATGTAAAATTTGGT-3'
Primer reverse:
5'-GGTGGTGGATCCTTAGAACATGCCACCTCCCAT-3'
CATATG - NdeI restriction site
GGATCC- BamHI restriction site
TTA - stop codon
Figure 1.2: The primers used to amplify hHSP60; 
the coding sequence is underlined.
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STEP TEMPERATURE TIME
Initial Denaturation 95ºC 10 min
Denaturation 95ºC 1 min
Annealing 55ºC 1 min 35 cycles
Extension 72ºC 1 min 40 sec
Final Extension 72ºC 10 min
Figure 1.3: The PCR parameters.
Figure 1.4: Schematic representation of pET15b.
The amplified coding sequence of the gene was quantified on a 0.8% agarose TBE gel 
and digested with  NdeI and  BamHI restriction enzymes; afterwards, the fragment was 
ligated  into  the  NdeI/BamHI site  of  the  pET15b plasmid (Novagen®),  thus  yielding 
HSP60-pET15b.  The chosen expression vector  allows the  N-terminal  portion of  the 
protein to be fused to a 6-His tag, which is useful for protein purification and detection 
by Western blot; moreover, the plasmid contains a thrombin cleavage site to facilitate 
removal of the tag after purification.
The resulting recombinant plasmid was used to transform E. coli XL1 Blue competent 
cells  by  heat  shock.  Cells  were  plated  on  a  LB-agar  plate  containing  100  μg/ml 
ampicillin and grown overnight at 37ºC. Colonies carrying the HPS60-pET15b plasmid 
were selected by colony PCR and subsequent digestion of the purified plasmid; finally, 
the vector was checked by automated DNA sequencing.
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1.2.3 Expression screening of the recombinant protein
The recombinant plasmid was used to transform the E. coli BL21 (DE3) strain by heat 
shock;  the  resulting  colonies  were  tested  for  protein  expression.  To test  for  protein 
expression,  a  single colony was inoculated  in  3 ml  of  LB medium, grown at  37ºC 
adding 100  μg/ml ampicillin and then incubated at 37ºC for 4 hours and at 20ºC and 
28ºC overnight after induction with IPTG (isopropyl β-D-1-thiogalactopyranoside) to a 
final concentration of 0.25 mM.
Cells were harvested by centrifugation at 9,000 rpm for 10 minutes at 4ºC and the pellet 
was resuspended in 2 ml of buffer A (20 mM TRIS-HCl pH 7.5, 0.5 M NaCl and 0.02% 
NaN3). Cells were disrupted by sonication and then centrifuged at 9,000 rpm for 10 
minutes at 4ºC. Samples from the total lysate and from the soluble fraction were loaded 
onto  a  SDS-PAGE gel  (12% polyacrylamide  resolving  gel  and  4% polyacrylamide 
stacking gel). Protein expression was evaluated by Western blot analysis using an anti-
histidine tag monoclonal antibody (Sigma-Aldrich®).
The protein was present in all the samples, in both the total fraction and the soluble 
fraction; the best soluble protein yield was obtained with an induction at 37ºC for 4 
hours.
1.2.4 Purification and crystallization trials
Immobilized Metal Ion Affinity Chromatography (IMAC)
E. coli BL21 (DE3) cells containing the plasmid HSP60-pET15b were inoculated in 10 
ml of LB medium containing 100 μg/ml ampicillin and shaken overnight at 37ºC. The 
10 ml overnight culture was transferred into 1 liter  of LB medium; the culture was 
grown at 37ºC under shaking until an OD600 of 0.8-1.0 was reached. Protein expression 
was induced by adding IPTG to a final concentration of 0.25 mM and the culture was 
further shaken at 37ºC for 4 hours. Cells were recovered by centrifugation at 8,000 rpm 
for 10 minutes at 4ºC and the pellet was resuspended in 50 ml of buffer A plus 10 mM 
imidazole. The sample was stored at -20ºC.
The  sample  was  thawed  and  0.1  mM  PMSF (phenylmethanesulfonyl  fluoride)  was 
added as protease inhibitor; then cell disruption was carried out by sonication and the 
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sample was centrifuged at 9,000 rpm for 10 minutes at 4ºC to remove cell debris.
The  soluble  fraction  was  directly  loaded  onto  a  Nickel  Sepharose  column  (5  ml 
prepacked column, HisTrap™ FF, Amersham Biosciences) preequilibrated with buffer A 
plus 10 mM imidazole. After loading, the column was further washed with buffer A and 
10 mM imidazole until the U.V. absorption at 280 nm returned to the baseline.
A gradient was applied to the column ranging from 10 mM to 500 mM imidazole. The 
fractions containing the target protein were collected and loaded onto a SDS-PAGE gel.
Size exclusion chromatography (SEC)
The protein was dialyzed against buffer B (20 mM TRIS-HCl pH 7.5, 0.15 M NaCl and 
0.02% NaN3) and 2.5 mM CaCl2.
Subsequently, the protein was concentrated to 1.0 mg/ml in an Amicon ultrafiltration 
cell  (Millipore™)  and  15  units  of  thrombin  were  added;  digestion  was  performed 
overnight at 20ºC.
The protein was concentrated to 2 ml in an Amicon cell and loaded onto a Superdex 
G200 gel filtration column, preequilibrated in buffer B. Gel filtration chromatography 
was performed to further purify the target protein and to remove thrombin and the 6-His 
tag. The effectiveness of thrombin cleavage was evaluated by Western blot.
The fractions containing the target protein were collected and loaded onto a SDS-PAGE 
gel.
Ion Exchange Chromatography (IEC)
A further purification step was performed with an anion exchange chromatography.
After Nickel Sepharose affinity chromatography, the protein was dialyzed against buffer 
C (20 mM TRIS-HCl pH 8.0 and 0.02% NaN3). The sample was loaded onto an anion 
exchange column (Hi Trap™ DEAE FF, Amersham Biosciences).  After  loading,  the 
column was further washed with buffer C until the U.V. absorption at 280 nm returned 
to  the  baseline.  Elution  was  achieved  by  a  step  gradient  increasing  the  salt 
concentration, from 0 to 0.5 M NaCl. The flow-through and the elution fractions were 
analyzed by SDS-PAGE.
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Crystallization trials
The protein sample was dialyzed against buffer D (20 mM TRIS-HCl pH 7.5 and 0.02% 
NaN3).  The protein was concentrated to 15-20 mg/ml by ultrafiltration (Amicon and 
Centricon centrifugal filter devices, Millipore™) and crystallization trials were set up 
using the hanging drop vapor diffusion technique using 24-well plates (MULTIWELL, 
Falcon™). Drops were formed by mixing 1 μl of protein solution with 1 μl of precipitant 
solution.  To screen 96 different crystallization solutions,  a commercial  kit  was used 
(Structure Screens 1 and 2, Molecular Dimensions Limited).
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1.3 Crystallization
1.3.1 Crystallization theory
Obtaining a crystallin form of the desired protein represents a crucial and often the most 
difficult step in order to determine the three-dimensional structure of a protein by X-ray 
diffraction.
Macromolecules are very complex systems, characterized by several physico-chemical 
parameters, that can change as a function of temperature, pH, ionic strength, solvent 
composition  and  other  environmental  variables;  for  this  reason,  the  crystallization 
process is necessarily empirical.
As a general rule, the reduction of the solubility of a protein solution results in the 
formation  of  an  amorphous  precipitate;  however,  when  appropriate  conditions  are 
selected, protein crystallization can occur.
The phase diagram represents the solubility of a protein as a function of the precipitant 
concentration.
Figure 1.5: A phase diagram for a hypothetical protein.
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In a saturated solution a solid phase exists in equilibrium with molecules in solution, i. 
e.  crystals  do  not  grow,  since  any  increase  in  the  proportion  of  solid  phase  is 
counterbalanced by an equivalent dissolution. Instead, crystal growth may occur in a 
supersaturated solution, in which a solid and a liquid phase are not at equilibrium and in 
which the solute moves from the liquid to the solid phase.
The supersaturated region can be divided into a labile region, where crystals can form 
and  grow,  and  a  metastable  region,  where  crystals  can  only grow.  If  the  system is 
pushed deeply into the labile region, the crystals obtained will be numerous, but small 
and afflicted with growth defects.
In order to obtain a few and big crystals, crystal growth should begin in the labile region 
just beyond the metastable region; in this way only a few crystals will form in the labile 
region and then, by depletion of the protein in solution, the system will return in the 
metastable region, where the few crystals previously formed will continue to growth.
Proteins in a crystal  are completely solvated; indeed, protein crystals  present a high 
water content, ranging from 30% to 80%.
Commonly used precipitants can be divided into: inorganic salts, organic solvents and 
long-chain polymers.
Inorganic salts are charged and consequently they can decrease the solubility of proteins 
by competition for water molecules. They also change the ionic strength of the solution. 
The ionic strength (μ) depends both on the concentration of the salt (c) and on its charge 
(z), according to the following relation:
μ = 1 / 2 Σ ci * zi2
At  low  salt  concentration,  protein  solubility  increases  (“salting  in”  effect)  as  salt 
concentration  increases,  because  interactions  between  proteins  and  water  molecules 
become more favourable. Instead at high salt concentration, protein solubility decreases 
(“salting out” effect) as salt concentration increases, because protein and salt have to 
compete to interact with water molecules; the “salting out” effect can be exploited to 
create conditions suitable for protein crystallization.
Since ionic strength depends on the square of the charge, bivalent and trivalent ions are 
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preferable; another aspect to be taken into account is the solubility of the salt in water,  
which should be high enough to avoid salt precipitation.
Commonly used inorganic salts are sulfates, phosphates and citrates.
Organic solvents reduce protein solubility by lowering the dielectric constant of the 
solvent. Commonly used organic solvents are: ethanol, isopropanol, dioxane, DMSO 
(dimethyl sulfoxide) and MPD (2-methyl-2,4-pentanediol).
Polyethylene  glycols  (PEGs)  are  linear  polymers  produced  in  various  lengths, 
containing from several to many hundred monomers. Like organic solvents, they lower 
the dielectric constant of the solvent; moreover, they show volume exclusion properties, 
forming a reticulum with water molecules, from which proteins are excluded.
All  PEG sizes  from Mr 400 to  20,000 have provided protein crystals,  but the most 
commonly used are those in the range from 2,000 to 6,000; commonly PEGs are used in 
concentrations from 5% to 30%.
Other factors that could affect protein crystal growth are:
• homogeneity and purity of the protein solution. The presence of contaminants or 
even  different  isoforms  of  the  same  protein  can  hinder  formation  and 
reproducibility of protein crystallization; these contaminations may be revealed 
by SDS-PAGE or IEF (isoelectrofocusing) analysis;
• protein concentration can vary from 5 mg/ml to 50 mg/ml;
• pH; it is a very important parameter in protein crystal formation. The optimum 
pH value is searched taking into account the protein stability at various pHs and 
that protein solubility reaches a minimum at the protein isoelectric point; also 
the  buffer  chosen  to  maintain  the  pH constant  can  affect  the  crystallization 
process;
• temperature; crystallization trials are kept at constant temperature, usually 4°C 
or 20°C. Crystallization occurs slowlier at colder than at warmer temperatures;
• time; it is quite variable and can range from a few hours to several months;
• presence  of  substrates,  inhibitors,  coenzymes  and  ligands.  Sometimes  the 
addition of these compounds can favour crystallization; their  effect is  due to 
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fixing an enzyme or a protein in a more compact and stable form;
• metal ions.
In addition, microheterogeneity of the protein solution may prevent crystal formation; 
common sources of microheterogeneity are the following: 
• presence, absence or variation in a bound prosthetic group, substrate, coenzyme, 
inhibitor or metal ion;
• variation in length or composition of the carbohydrate moiety of a glycoprotein;
• proteolytic  modification  of  the  protein  during  the  course  of  isolation  or 
crystallization;
• oxidation of sulfhydryl groups during isolation;
• reaction with heavy metal ions during isolation or storage;
• presence, absence or variation in post-translational side chain modifications such 
as methylation, amidation and phosphorylation;
• microheterogeneity in the amino or carboxy terminus or modification of termini;
• variation  in  the  aggregation  or  oligomeric  state  of  the  protein  due  to 
association/dissociation;
• conformational instability due to the dynamic nature of the molecule;
• microheterogeneity due to the contribution of multiple but nonidentical genes to 
the coding of the protein, isozymes;
• partial denaturation of the sample;
• genetically different animals, plants or microorganisms that make up the source 
of protein preparations;
• bound lipids, nucleic acids or carbohydrates, or substances such as detergents 
used in the isolation [21].
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1.3.2 Crystallization techniques
The  most  commonly used  technique  to  reach  the  supersaturation  state  is  the  vapor 
diffusion method. This method is based on the transport of either water or some volatile 
agents between a microdrop of protein solution and a much larger precipitant solution 
(reservoir  solution);  the  microdrop  and  the  reservoir  solution  come  to  equilibrium 
through the vapor phase and the final equilibration conditions are those of the reservoir 
solution, due to its much larger volume.
The protein and the precipitant solution are usually mixed in a 1:1 ratio; reagents in the 
reservoir  solution  are  more  concentrated  than  in  the  drop  and  consequently  water 
gradually evaporates from the microdrop. When a supersaturated state is reached in the 
drop, protein crystals may form. 
The vapor diffusion method can be divided into the hanging drop and the sitting drop 
techniques.
In the first method a drop containing a mixture of protein and precipitant solution of a 
size ranging from 100 nl to 5 μl is dispensed on a microscope cover glass; the drop is 
then  sealed  with grease  or  mineral  oil  into  a  well  containing  the  reservoir  solution 
(usually 300 μl).
Figure 1.6: The hanging drop technique.
This method requires only small amounts of material and, as a consequence, it is ideal 
for screening a large number of conditions.
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In the sitting drop method, the drop containing the protein and the precipitant solution 
mixed is  dispensed on a  microbridge,  which  is  placed inside  a  well  containing  the 
reservoir solution; the well is then closed with a microscope cover glass and sealed by 
grease or mineral oil.
Figure 1.7: The sitting drop technique.
The sitting drop technique requires larger volumes of protein solution than the hanging 
drop technique, ranging from 5 to 40 μl, and it is usually used to improve crystallization 
conditions previously identified by the hanging drop technique.
Another crystallization method is the dialysis technique; it is based on diffusion and 
equilibration of small precipitant molecules through a semipermeable membrane as a 
means of slowly approaching the supersaturated state.
The  protein  solution  is  contained  inside  a  dialysis  cell  with  a  semi-permeable 
membrane, that allows the passage of small molecules and ions and not of the protein 
molecules  through  its  pores.  The  dialysis  cell  containing  the  protein  solution  is 
submerged into a much larger volume of precipitant solution. Following equilibration 
against the precipitant solution, the protein solution within the dialysis cell can reach 
supersaturation and thus eventually protein crystals may appear.
The  main  disadvantage  of  this  technique  is  the  relatively  large  amount  of  protein 
solution  required  (10-100  μl  in  each  trial).  An  important  advantage  of  the  dialysis 
method is  that  the  precipitant  solution  can  be  easily  varied,  simply by moving the 
dialysis tube from one solution to a different one.
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1.3.3 Solution of the phase problem
X-ray diffraction is used to determine the 3D structure of a target protein. The electron 
density distribution within  the unit  cell  can  be described as  the inverse  3D Fourier 
transform of  the  structure  factors;  structure  factors  are  defined  as  the  ratio  of  the 
radiation scattered by any real sample to that scattered by a single electron placed at the 
origin.‌
The structure factor,  F(h,k,l),  is a complex number describing amplitude (│F│) and 
phases  (eiφ)  of  a  wave diffracted  from crystal  lattice  planes  characterised  by Miller 
indices h, k,  l.  Both amplitude and phases must be known in order to calculate the 
electron density map. In X-ray data the intensity of each reflection is proportional to the 
square of the structure factor amplitude, but all phase information is systematically lost.
Commonly  used  ways  to  recover  the  phases  are  Molecular  Replacement,  Multiple 
Isomorphous Replacement and Multiwavelength Anomalous Diffraction.
Molecular Replacement (MR)
The unknown phases  of  the target  protein are  obtained using phases  from a known 
model. It is accepted that molecular replacement will be straightforward if the protein 
sequence identity of the two proteins is  greater  than 40%; it  becomes progressively 
more difficult as the model shares less sequence identity.
To place the model structure in the correct orientation and position in a different unit 
cell, three rotational angles and three translational parameters are required; therefore, 
the  molecular  replacement  is  a  6-dimensional  problem.  However  it  is  possible  to 
separate this into two 3-dimensional problems. First, a rotation function is computed to 
find the three rotational angles and thus to orient the known structure within the unit 
cell; after that, a translation function is used to place the oriented model in the cell. The 
phases obtained from molecular replacement can be used together with the experimental 
intensities to calculate the electron density map.
Multiple Isomorphous Replacement (MIR)
MIR is based on the introduction of a small number of heavy atoms (atoms containing 
many electrons)  into  the  protein  crystal.  The  native  and the  heavy atom derivative 
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crystal should be isomorphus, that is crystal form and unit cell dimensions should be 
unchanged.  Derivatives  are  usually  prepared  by  soaking  the  crystal  in  a  solution 
containing a heavy atom. The data from a native crystal and a derivate are compared 
and thus the differences in scattered intensities are measured; by using this information, 
a Patterson difference map can be computed and heavy atom coordinates in the unit cell 
can be calculated. Two derivate crystals are sufficient to determine the phases in theory; 
however,  due to errors in the experimental results  and imperfect isomorphism, more 
than two derivates are often required.
Multiwavelength Anamalous Diffraction (MAD)
The MAD technique exploits the ability of the inner electrons of atoms to absorb X-rays 
at particular wavelengths. Due to the anomalous dispersion effect, the X-rays reemitted 
from these scatterers have a small  shift  in both amplitude and phases. According to 
Friedel’s law, structure factors related by opposite Miller indices, called Friedel mates, 
show equal reflection intensities:
│F(h,k,l) │ = │F(-h,-k,-l) │
Indeed the resonant frequencies of most elements in biological molecules are far below 
the  energies  used for  diffraction  experiments.  However,  elements  of  atomic  number 
from 24 to 92 have resonance frequencies consistent with X-ray diffraction experiments. 
If the frequencies of the X-rays fall near an absorption frequency of an atom, Friedel’s 
law does not hold and the differences between Friedel’s mates in scattered intensities 
can be used to  calculate  the position of  the anomalous scatterer  in  the unit  cell  by 
Patterson methods. 
MAD  data  collection  is  performed  at  two  or  more  different  wavelengths  near  the 
absorption  edge  of  the  scatterer.  A commonly  used  atom  for  MAD  technique  is 
selenium,  by  replacing  the  natural  sulphur  containing  amino  acid  methionine  with 
selenomethionine.
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1.4 Results and discussion
The human HSP60 gene was inserted into the pET15b plasmid and used to transform E. 
coli BL21 (DE3) strain cells.
According to the Western blot analysis, the protein was expressed in soluble form in 
appreciable quantity in each of the three induction conditions tested (37ºC for 4 hours, 
20ºC overnight and 28ºC overnight).
Figure 1.8: Western blot analysis of HSP60-pET15 E. coli BL21. The total fractions (left) are referred to 
induction at 20ºC overnight (lane 1) and 28ºC overnight (lane 2), while the soluble fractions (right) to 
induction at 37ºC for 4 hours (lane 1), 28ºC overnight (lane 2) and 20ºC overnight (lane 3).
When 1 liter of culture was grown, the induction was best carried out at 37ºC for 4 
hours, with a yield of 15-20 mg of protein after IMAC chromatography.  The elution 
pattern  from the  IMAC column showed  two  peaks;  the  protein  was  present  in  the 
second, corresponding to an imidazole concentration of about 200 mM. The protein 
showed a good purity grade, but further purification steps were still required.
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Figure 1.9: Elution profile of HSP60 from Nickel Sepharose affinity column. 
The blue line corresponds to the UV absorbance and the red line to the imidazole gradient.
Figure 1.10: SDS-PAGE analysis of HSP60 obtained after Nickel Sepharose affinity chromatography.
The target protein is present in the second peak with a good purity grade.
Lanes 1 to 5: fractions corresponding to the second peak.
Proteolitic removal of the 6-His tag was performed by dialysis of the protein against a 
suitable  buffer  and the  subsequent  addition of  thrombin;  complete  tag  removal  was 
confirmed by the disappearance of the band from a Western blot with an anti-histidine 
tag monoclonal antibody.
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Figure 1.11: HSP60 before and after His-tag proteolytic removal (lane 1 and lane 2, respectively). 
Then the protein was further purified by size exclusion chromatography. The protein 
was present in the main peak of the chromatogram.
Figure 1.12: Elution profile of HSP60 from Superdex G200 size exclusion column. 
The blue line corresponds to the UV absorbance.
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Figure 1.13: SDS-PAGE analysis of HSP60 obtained after size exclusion chromatography. 
Lane 1 and 2: fractions corresponding to the main peak.
The protein was concentrated to 20 mg/ml and crystallization trials were set up using 
the  hanging  drop  vapor  diffusion  technique.  None  of the  cystallization  trials  gave 
crystals suitable for X-ray data collection. This is probably due to the heterogeneity of 
the purified protein.
Figure 1.14: SDS-PAGE (10% resolving gel) analysis of HSP60 used in crystallization trials. 
Lane 1: 1 μl of HSP60 after concentration was loaded.
The heterogeneity of the sample may be explained with protein degradation due to the 
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presence  of  contaminant  proteases;  accordingly,  the  entire  purification  protocol  was 
repeated adding a protease inhibitor cocktail (Complete, EDTA-free, Roche) to the cells 
just before sonication and adding EDTA (ethylenediaminetetraacetic acid) 5 mM in all 
the  buffers  used  after  Nickel  Sepharose  elution.  Nevertheless,  no  appreciable 
improvement was achieved in the final purified protein; however, new crystallization 
trials were set up.
As a further purification step,  an anion exchange chromatography was performed in 
order  to  obtain  a  more  homogeneous  sample;  the  protein  obtained  after  the  IMAC 
chromatography  was previously dialyzed against  a  buffer  with a  slightly higher  pH 
value and without NaCl and then loaded onto a DEAE column.
Figure 1.15: Elution profile of HSP60 from DEAE column. 
The blue line corresponds to the UV absorbance and the red line to the NaCl gradient.
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Figure 1.16: SDS-PAGE analysis of HSP60 obtained after anion exchange chromatography. 
L: sample loaded. FT: flow-through. Lane 1: elution with 20 mM NaCl. Lane 2: elution with 
50 mM NaCl. Lane 3: elution with 100 mM NaCl. Lane 4 to 7: elution with 500 mM NaCl.
The protein was completely bound to the column and it was eluted at high values of salt 
concentration (100 and 500 mM NaCl). The fractions containing the pure protein were 
collected and crystallization trials were set up.
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1.4 Conclusions and prospectives
Human  HSP60  was  expressed  in  the  prokaryotic  system  E.  coli and  a  purification 
protocol was set up. The protein was purified with an IMAC chromatography, followed 
by  removal  of  the  His-tag  and  a  size  exclusion  chromatography.  The  protein  was 
dialyzed in a suitable buffer, concentrated and crystallization trials were set up.
Nevertheless, no crystal suitable for X-ray experiments has yet been obtained. This is 
probably due to protein heterogeneity and degradation; the use of an inhibitor cocktail 
and EDTA has not avoided protein degradation.
The undergoing experiments are focused on improving the purification protocol;  the 
addition of an anion exchange chromatography step seems encouraging to reach this 
goal.
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 2. Activation-induced cytidine deaminase
2.1 Introduction
2.1.1 Somatic hypermutation and class switch recombination
Vertebrates have evolved the immune system as a defence barrier against pathogens; it 
can be divided into innate and adaptative immune system, which is composed of B and 
T lymphocytes and is characterized by extreme specificity for foreign antigens.
The molecules produced by lymphocytes able to recognize pathogenic antigens in a 
very specific manner are antibodies and TCR (T cell receptors), synthesized by B cells 
and T cells, respectively. Antibodies are produced in a membrane-bound form, which is 
involved in B cell activation, and in a soluble form, which is responsible for antigen 
clearance.
The antibody, also called immunoglobulin (Ig), comprises two identical pairs of heavy 
chains (IgH) and of light chains (IgL) [1].
Each of the two light chains is covalently bound to one of the two heavy chains through 
a disulfide bond; the two heavy chains are also bound to each other by disulfide bonds. 
Both  the  heavy  chains  and  the  light  chains  contain  immunoglobulin  domains  (Ig 
domains), composed of two sandwiched β-pleated sheets pinned together by a disulfide 
bridge. Both the heavy chains and the light chains are formed by an N-terminal variable 
(V) region and a C-terminal constant (C) region; in the light chains, both the V region 
and the C region comprise only one Ig domain,  whereas in the heavy chains the C 
region has 3 or 4 Ig domains and the V region contains only one Ig domain [1].
The  V regions  of  IgH and IgL contain  the  antigen-binding  site;  since  the  antibody 
consists of two IgL and two IgH, each antibody has two antigen binding sites. On the 
other hand, the C region of IgH determines the biological properties of the antibody, 
since it is involved in interactions with molecules and cells of the immune system.
There are two types of IgL, called k o λ; as a consequence, each antibody comprises two 
identical IgL k or two identical IgL λ [1].
The antibodies expressed in soluble form and in membrane-bound form differ in their 
amino acid sequence in the last Ig domain of IgH; the former, which are secreted into 
the blood and other extracellular fluids, contain charged and hydrophilic residues, while 
the latter, present in the membrane of B cells, have a certain number of hydrophobic 
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residues, followed by basic residues.
The extreme specificity for foreign antigens shown by the adaptative immune system is 
based on the generation of a myriad of receptors for antigens of virtually unlimited 
diversity;  this  is  due  to  the  somatic  recombination  of  immunoglobulin  genes  of  B 
lymphocytes. Germ line antigen receptor genes include an array of variable (V), diverse 
(D), joining (J) and constant (C) segments; D segments are present only in IgH locus. V, 
D and J segments encode for the variable region,  while C segments encode for the 
constant region; there are three separate loci encoding for IgH, IgL k and IgL λ, located 
on chromosome 14, 2 and 22, respectively [1].
Figure 2.1: Chromosomal organization of the immunoglobulin H, k and λ loci [1].
During lymphocyte differentiation, a somatic recombination of a V, a D and a J segment 
generates  the  antigen  recognition  site  of  the  receptor  in  each  lymphocyte  in  a 
completely random process. First, a single D segment is joined to a single J segment and 
then  this  partially  rearrenged  D-J  gene  is  joined to  a  single  V segment.  Moreover, 
junctional diversity is present in the junctions between V and D and between D and J in 
IgH and between V and J in IgL; this is due to the random insertion or deletion of some 
nucleotides in these points. The combinatorial diversity given by V, D and J segments 
and  the  junctional  diversity  allow  the  generation  of  a  pletora  of  different  antigen 
receptors, virtually able to recognize every possible antigen; the primary repertoire of 
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immunoglobulins is thus generated in an antigen-indipendent manner.
The IgH locus has a number of constant regions, each preceded by a high repetitive and 
non-coding  sequence  called  switch  region.  Before  encountering  the  antigen,  the 
immunoglobulins produced by B cells are IgM or IgD. In particular, after leaving the 
bone marrow to colonize secondary limphoid organs, B cells express surface IgD of the 
same specificity as surface IgM; this is due to alternative splicing of a pre-messanger 
RNA comprising both heavy chain Cμ and Cδ regions.
After encountering its cognate antigen, B cells have another chance to further diversify 
their  receptors;  in  germinal  centers  immunoglobulin  genes  undergo two indipendent 
mutational events, called somatic hypermutation (SHM) and class switch recombination 
(CSR). As a consequence, higher affinity immunoglobulins with different isotypes are 
generated [2, 3].
SHM consists in the introduction of nucleotide changes, usually point mutations, in the 
V(D)J segments of the variable region of the immunoglobulin gene.  If  the acquired 
mutations increase the receptor affinity for the antigen, the B cells will proliferate and 
differentiate into either plasma cells, that produce antibodies, or memory B cells. On the 
other  hand,  if  the  acquired mutations  during  SHM diminish the  affinity or  produce 
deleterious effects for the final protein, the B cells will be rendered anergic [2, 3].
Mutations are produced at a rate of 10-3-10-4 per cell division, that is one million times 
greater than typical somatic cell mutation frequency. The mutations begin at about 200 
bp downstream from the Ig gene transcription start site, reach a peak over the variable 
region, taper off at 2 kb downstream from the promoter and end before reaching the 
constant region [2].
Mutations are about equally divided between transcribed and non-transcribed strands. 
Of the 50% of mutations at G/C sites, 37% are within the WRC hot spot motif, where W 
is A or T and R is A or G; of the A/T mutations, 34% occur at A sites and 16% at T sites  
on the non-transcribed strand [2].
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Figure 2.2: Generation of the secondary antibody repertoire in IgH locus. SHM implies the introduction 
of nucleotide substitutions (depicted as arrows) in the rearranged V(D)J region (orange, yellow and red, 
respectively). CSR consists in the exchange of the IgH Cμ segment for one of the downstream C 
segments (blue boxes), in the figure Cγ1 giving rise to IgG1; the recombination takes place between two 
switch regions (green ovals) [3].
CSR is a region-specific recombination reaction between two switch regions of the IgH 
locus. This reaction implies the replacing of the Cμ constant region by a downstream 
constant  region;  as  a  consequence,  the  Ig  will  acquire  different  effector  functions. 
Double strand breaks are generated within the donor switch region (Cμ) and a recipient 
switch region of a downstream C region; the C regions between the two break sites are 
deleted as a circular DNA molecule and the VDJ region and the C region are joined 
together by non-homologous end joining [2, 3].
According  to  the  constant  region  of  the  IgH,  antibodies  can  be  divided  into  five 
isotypes: IgA, IgD, IgE, IgG and IgM; additionally, IgA can be further divided in IgA1 
and IgA2 and IgG in IgG1, IgG2, IgG3 and IgG4 [1].
IgMs are present in the membrane of B cells before antigen encounter; in the secretory 
form,  they  are  pentameric  and  play  an  important  role  in  the  activation  of  the 
complement system [4].
IgDs  are  present  as  membrane-bound  proteins  in  B  cells  before  antigen  encounter. 
Additionally, they can be found in the blood at low concentration; they are also present 
in nasal, lacrimal, salivary and bronchial fluids [5].
IgAs are secreted as monomers, dimers and trimers. IgA1s are produced by B cells in 
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bone marrow and they can be found in the serum, while IgA2s are produced by B cells 
in mucosae and are secreted into maternal milk, saliva and tears. In particular, IgAs 
represent the main element of the humoral immune response which provides protection 
against pathogens at mucosal surfaces [6].
IgEs  are  secreted  as  monomers  and  can  be  found  in  the  blood  at  a  very  low 
concentration. They are involved in the immune response against parasitic worms and 
play a very important role in allergy [7].
IgGs are the most abundant antibodies in the body;  they are secreted as monomers. 
They have the longest serum half-life of all immunoglobulin types. They can bind many 
kinds  of pathogens,  such as viruses,  bacteria  and fungi.  The IgG subclasses  exhibit 
different functional activity; IgG1s and IgG2s are the most abundant IgGs in the blood. 
IgG1s, IgG2s and IgG3s are involved in the activation of the complement cascade. IgG 
is the only isotype of immunoglobulin able to undergo transplacental transport, thereby 
providing protection to the fetus [1].
2.1.2 Human activation-induced cytidine deaminase
AICDA was first identified in 1999 as a gene specifically expressed in B cells after CSR 
activation [8]. Subsequently, in an experiment performed with AICDA-deficient mice, 
AICDA was proved to be essential for both CSR and SHM [9]. Moreover, mutations in 
the human AICDA gene were found to be associated with an immune deficiency called 
Hyper-IgM  syndrome  type  2;  patients  with  the  autosomal  recessive  form  of  the 
pathology showed three major abnormalities: the lack of immunoglobulin class switch 
recombination, the absence of immunoglobulin somatic hypermutation and lymph node 
hyperplasia due to the presence of giant germinal centers [10].
Interestingly,  when  AICDA  was  heterologously  expressed  in  fibroblasts,  it  was 
sufficient to promote both CSR and SHM on transcribed substrates, thus proving that 
AICDA is the only B-cell specific factor required to initiate these reactions [11, 12].
AICDA is  homologous  to  APOBEC1,  a  protein  involved  in  the  editing  of  C  to  U 
nucleotide  in  apolipoprotein  B  and  neurofibromatosis-1  mRNA;  AICDA was  thus 
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suggested to be a mRNA deaminase involved in editing of a mRNA encoding for a 
protein,  possibly an endonuclease,  responsible  for CSR and SHM. Some alternative 
hypotheses were proposed according to which AICDA would deaminate cytidines on 
double strand DNA (dsDNA), single strand DNA (ssDNA) or DNA/RNA hybrids.
At present the ssDNA deamination model is the most widely accepted. As a matter of 
fact,  AICDA can  deaminate  ssDNA in  vitro,  with  the  same  sequence  preference 
observed in vivo in B cells, while dsDNA is refractory to the enzyme activity [13]. 
Additionally, AICDA was reported to interact with the switch regions of DNA in B cells 
undergoing CSR [14]. Before the identification of AICDA, SHM and CSR were known 
to require transcriptional activity of variable regions and switch regions, respectively; 
since transcription can, at least transiently, expose DNA in a single strand configuration, 
at  present  it  is  hypothesized  that  transcription  of  the  immunoglobulin  gene  during 
germinal center reactions can allow AICDA to access its substrate ssDNA [2, 3].
The U:G mismatch generated by the AICDA catalyzed reaction can undergo different 
processes that lead to SHM:
• the mismatch is replicated over, thus producing a transition mutation at the C:G 
pair (phase 1A);
• uracil is removed by uracil-N-glycosylase (UNG), thus resulting in an abasic 
site; upon replication, both transitions and transversions at C:G pairs can occur 
(phase 1B); 
• the mismatch is recognized by mismatch repair (MMR) factors, thus generating 
mutations at A:T pairs by error-prone patch repair (phase 2).
Alternatively, the abasic site generated by UNG can be substrate for an apyrimidinic 
endonuclease (AP), producing a nick in the DNA strand containing the abasic site; this 
nick can be repaired by the base-excision repair pathway, eliminating the DNA lesion 
caused  by  AICDA,  or  can  be  processed  by  non-homologous  end  joining  (NHEJ), 
leading to CSR.
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Figure 2.3: DNA deamination by AICDA in SHM and CSR. The transition is the exchange of a 
purine for a purine (A↔G) or a pyrimidine for a pyrimidine (C↔T), while the transversion is the 
exchange of a purine for a pyrimidine or a pyrimidine for a purine (A/G↔C/T) [3].
Transcriptional regulation
AICDA expression is restricted to activated B cells. The specificity and the levels of 
AICDA  transcription  are  regulated  by  a  complex  combination  of  transcriptional 
activators and repressors. 
Gene expression is dependent on signaling pathways that mediate the activation of B 
cells  in  germinal  centers,  such  as  those  mimicked  by  lipopolysaccharide,  IL4, 
transforming  growth  factor  β  and  CD40  ligation;  accordingly,  janus  kinase-signal 
transducer and activator of transcription and nuclear factor-kappa B (NF-kB) pathways 
seem to be involved [15].
An  intronic  E-box  element  present  in  the  AICDA gene  was  reported  to  regulate 
positively AICDA transcription through the binding of the helix-loop-helix transcription 
factor  E47;  additionally,  this  intronic  element  downregulates  AICDA transcription 
through the binding of the inhibitor of DNA binding helix-loop-helix protein ID3 [16].
AICDA transcription is also regulated by binding of paired box gene 5 (PAX5) and the 
inhibitor of DNA binding 2 (ID2) factors to the promoter region [17].
Additionally, binding sites for ubiquitous Sp transcription factors were identified in the 
AICDA promoter; Sp are a family of transcription factors involved in the regulation of 
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many different promoters through binding to GC box or GT motifs [18].
Post-transcriptional regulation
A microRNA previously known to play a crucial role in activation of B cells, miR-155, 
was found to be upregulated in murine B cells undergoing CSR; this microRNA targets 
a  conserved  site  in  the  3'-untranslated  region  of  the  mRNA  encoding  AICDA. 
Disruption  of  this  site  in  vivo  was  observed  to  cause  a  deregulation  of  AICDA 
expression, increasing the level of both CSR and SHM [19]. Additionally, mutations in 
miR-155 binding site in the 3'-untranslated region of AICDA mRNA determined an 
increase  in  AICDA mRNA half-life  and  in  the  protein  level  [20].  Deregulation  of 
AICDA activity resulted in mutations on non-target genes,  such as the antiapoptotic 
gene  Bcl6, and in an increase in  Myc-Igh translocations, suggesting that miR-155 can 
act as a tumor suppressor by reducing potentially oncogenic translocations produced by 
AICDA [19, 20].
Subcellular localization
AICDA activity is  also regulated by controlling  the  protein subcellular  localization; 
most AICDA protein is located in the cytoplasm, since AICDA was observed in the 
nucleus in only 3-11% of activated B cells [2]. Indeed, the protein possesses a nuclear 
export signal in the last C-terminal 10 amino acids; deletion of this export signal caused 
nuclear accumulation of the enzyme, but did not increase the number of mutations in 
immunoglobulin genes [2].
Post-translational modifications
AICDA activity is enhanced upon phosphorylation at Ser38 by protein kinase A (PKA). 
Mice expressing only S38A AICDA have 70% less CSR and SHM, thus suggesting that 
this phosphorylation is required for efficient levels of both SHM and CSR [21]. Ser-38 
phosphorilation is required for AICDA to interact with replication protein A (RPA) [2].
Other three phosphorylation sites were identified (Thr27, Thr140 and Tyr184), but so 
far their physiological role remains unclear [21].
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AICDA targeting to Ig locus
A not yet clarified point is the way AICDA specifically targets Ig genes and not other 
genes; moreover,  the enzyme activity is  restricted only in specific regions within Ig 
genes, that are the variable regions in SHM and the switch regions inside the constant 
regions in CSR.
Ig  locus  transcription  is  strictly  required  for  AICDA activity  and  removal  of  Ig 
promoters  dramatically  decreases  SHM;  additionally,  the  rate  of  Ig  transcription 
correlates with the rate of SHM and CSR [3].
It  was  hypothesized  that  this  enzyme may be  loaded  on  the  transcription  initiation 
complex,  to  follow RNA polymerase  II  during  elongation  and  that  it  stochastically 
dissociates,  creating  the  decaying  pattern  of  mutations  observed  in  SHM  [21]. 
Nevertheless,  transcription  alone  is  not  sufficient  for  targeting  AICDA,  since  other 
genes transcribed at high levels in B cells are not mutated.
Ig cis-acting elements, such as the intronic enhancer (iE) and the matrix attachment 
regions (MAR) have been suggested to play a role in AICDA targeting to Ig locus [2].
Additionally,  some  epigenetic  modifications  may  be  involved.  Hyperacetylation  of 
histone  3  in  switch  regions  correlates  with  induction  of  CSR and  Ig  transcription, 
suggesting that this modification may mark IgH locus for AICDA to initiate the CSR 
reaction.  Histone  4  hyperacetylation  of  switch  regions  correlates  with  CSR  in  an 
AICDA-dependent manner,  suggesting that  this  modification may be downstream of 
AICDA activity and play a role in recruiting double strand break repair factors [3].
AICDA in B-cell lymphomas
About 95% of diagnosed lymphomas are of B-cell origin and the majority of them are 
thought to originate from germinal-center or post germinal-center B cells. A common 
hallmark of B-cell lymphomas is the presence of chromosome translocation causing the 
juxtaposition of the Ig locus and a proto-oncogene. Some of these translocations are 
related  to  a  specific  type  of  B-cell  lymphomas,  such  as  BCL-1-Ig  translocation  in 
mantle-zone lymphoma, BCL-2-Ig translocation in follicular lymphoma and c-MYC-Ig 
translocation in  Burkitt  lymphoma; this  chromosome fusion causes  the  oncogene to 
come  under  the  control  of  Ig  cis  sequences  and  its  deregulated  and  constitutive 
expression. Other common and characteristic features of particular B-cell malignancies 
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are mutations in tumor suppressor genes, such as  p53, retinoblastoma (RB),  p19 and 
ataxia telangiectasia mutated (ATM) [3].
At physiological AICDA expression levels,  c-MYC-IgH translocations are extremely 
rare;  this  suggests  that  in  physiological  situations  cellular  surveillance  mechanisms 
prevent the generation of chromosome translocations [3]. Mice lacking DNA-damage 
response proteins, such as ATM, histone 2A family member X (H2AX) and p53 binding 
protein  1  (53BP1),  are  prone  to  accumulate  chromosomal  breaks  and  aberrations 
associated with the IgH locus; in the case of H2AX and 53BP1, these mutations were 
reported to depend on the presence of AICDA. Moreover, B cells lacking p53 show a 
higher AICDA-dependent c-MYC-IgH translocation frequency [3, 22, 23].
2.1.3 APOBEC family
AICDA belongs  to  the  APOBEC  family,  which  comprises  enzymes  able  to  insert 
mutations in RNA and single strand DNA through deamination of cytidine to uridine 
[24 - 26 ].
APOBEC1 (apoB editing catalytic subunit 1, Apo1) is expressed in the small intestine, 
where it is responsible for editing of ApoB pre-mRNA; the deamination of cytidine 6666 
converts a glutamine codon (CAA) to a stop codon (UAA), thus generating a shorter 
form of the protein. The protein is the main component of the hydrophilic shell of the 
chylomicrons,  which  are  the  very  low-density  lipoproteins  involved  in  trasport  of 
triglycerides from the intestine to the tissues.
APOBEC2  (Apo2)  is  expressed  in  cardiac  and  skeletal  muscle;  the  enzyme  shows 
deaminase activity on cytidine and deoxycytidine in vitro,  but its  physiological role 
remains unknown.
The term APOBEC3 (Apo3) is referred to proteins (APOBEC-3A, -3B, -3C, -3DE, -3F, 
-3G, -3H) involved in the restriction of retrovirus and retrotransposons propagation. 
Apo3G was identified as a factor involved in HIV restriction. The protein is thought to 
be packed into the HIV virion and to exert its enzymatic activity on the nascent first 
DNA strand generated by reverse  transcription in  the target  cell;  as  a  consequence, 
Apo3G prevents the viral genome from integration into the cell's genome.
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The  APOBEC  enzymes  share  a  catalytic  domain  defined  by  a  conserved  cytidine 
deamination motif (H-X-E-X23-28-P-C-X-X-C); the residues of this motif coordinate a 
zinc atom, which is required for the nucleophilic attack in the deamination reaction.
Apo3B, Apo3DE, Apo3F and Apo3G have two catalytic domains containing the amino 
acids required for catalysis. Both domains of Apo3B are enzymatically active, while 
only the C-terminal domains of Apo3F and Apo3G are enzymatically active.
AICDA         -----------------------------------------MDSLLMNRRKFLYQFKNVR 19
APOBEC2       MAQKEEAAVATEAASQNGEDLENLDDPEKLKELIELPPFEIVTGERLPANFFKFQFRNVE 60
APOBEC1       ---------------------------------MTSEKGPSTGDPTLRRRIEPWEFDVFY 27
                                                         .  :  .   ::*  . 
AICDA         WAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNG-CHVELLFLR-YISDWDLDPGRCYR 77
APOBEC2       YSSGRNKTFLCYVVEAQGKGGQVQASRGYLEDEHAAAHAEEAFFN-TILP-AFDPALRYN 118
APOBEC1       DPRELRKEACLLYEIKWGMSRKIWRSSG----KNTTNHVEVNFIKKFTSERDFHPSMSCS 83
               .   .:          . . ..  . *    ::   *.*  *:.       :.*.    
AICDA         VTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIA 137
APOBEC2       VTWYVSSSPCAACADRIIKTLSKTKNLRLLILVGRLFMWEEPEIQ-AALKKLKEAGCKLR 177
APOBEC1       ITWFLSWSPCWECSQAIREFLSRHPGVTLVIYVARLFWHMDQQNR-QGLRDLVNSGVTIQ 142
              :**: * ***  *:  : . *    .: * * ..**:   : : .  .*: * .:*  : 
AICDA         IMTFKDYFYCWNTFVEN---HERTFKAWEGLHENSVRLSRQLRRILLP------------ 182
APOBEC2       IMKPQDFEYVWQNFVEQEEGESKAFQPWEDIQENFLYYEEKLADILK------------- 224
APOBEC1       IMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQNH 202
              **  .:: : *..**:    ..  :  :  :       . :   :               
AICDA         --LYEVDDLRDAFRTLGL---------------- 198
APOBEC2       ----------------------------------
APOBEC1       LTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR 236
Figure 2.4: Comparison of human AICDA, Apo2 and Apo1. The amino acids involved in coordination to 
the zinc atom and the conserved glutamate residues are shown in red and in yellow, respectively. 
Sequence alignment was performed using the program ClustalW 2.0 [27].
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At present there are two crystal structures of APOBEC family members, Apo2 and the 
C-terminal catalytic domain of Apo3G (Apo3G-CD2) [28, 29].
Figure 2.5: On the left an Apo2 (PDB ID 2NYT) monomer and on the right Apo3G-CD2 (PDB ID 3E1U) 
showing the catalytic residues and the zinc atom (red sphere) in the active site. The figures were 
generated using the program PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, 
Schrödinger, LLC).
The structures of the Apo2 monomer (residues 41-224) and of Apo3G-CD2 (residues 
197-380) show a common β-sheet core composed of 5 β-strands surrounded by 6 α-
helices.
In the active site of Apo2 and Apo3G-CD2, the active center zinc atom is coordinated 
by three conserved residues (H98, C128 and C131 in Apo2, H257, C288 and C291 in 
Apo3G-CD2); during the enzymatic reaction, a closely located water molecule acts as a 
hydrogen donor, while the conserved glutamate residue (E100 in Apo2 and E259 in 
Apo3G-CD2) serves as a proton shuffler.
54
2.2 Materials and Methods
2.2.1 The human AICDA clone
The plasmid with the full-lenght cDNA clone (IMAGE ID 4054915) of human AICDA 
was purchased from RZPD.  E. coli cells harbouring the plasmid vector pOTB7 were 
grown in 3 ml of LB medium containing 50 μg/ml chloramphenicol overnight at 37ºC.
After harvesting the cells by centrifugation, the GenElute™ Plasmid Miniprep kit was 
used to purify the plasmid.
2.2.2 Subcloning of AICDA gene
The protein coding sequence was subcloned into plasmids suitable for expression in E. 
coli.
First,  a  PCR reaction  was  used to  amplify the  coding sequence  of  the  protein;  the 
primers, the parameters of PCR and the plasmid maps are reported as follows.
pET15b:
Primer forward:
5'-GGTGGTCATATGGACAGCCTCTTGATGAAC-3'
Primer reverse:
5'-GGTGGATCCTTAAAGTCCCAAAGTACGAAA-3'
CATATG - NdeI restriction site
GGATCC- BamHI restriction site
TTA - stop codon
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pQE50, pET22b, pET28:
Primer forward:
5'-GGTGGTGGATCCATGGACAGCCTCTTGATGAAC-3'
Primer reverse: 
5'-GGTGGTAAGCTTGGAACCACGCGGAACCAGAAGTCCCAAAGTA
CGAAA-3'
GGATCC- BamHI restriction site
AAGCTT - HindIII restriction site
GGAACCACGCGGAACCAG – thrombin cleavage site
pGEX-4T-1:
Primer forward:
5'-GGTGGATCCATGGACAGCCTCTTGATGAACCGG-3'
Primer reverse:
5'-GGTGTCGACTCAAAGTCCCAAAGTACGAAATGC-3'
Primer reverse-His-tag:
5'-GGTGTCGACCTAATGATGATGATGATGATGAAGTCCCAAAGTACG-3'
GGATCC- BamHI restriction site
GTCGAC – SalI restriction site
TCA - stop codon
CTA - stop codon
ATGATGATGATGATGATG – His-tag
Figure 2.6: The primers used to amplify hAICDA; the coding sequence is underlined.
STEP TEMPERATURE TIME
Initial Denaturation 95ºC 10 min
Denaturation 95ºC 1 min
Annealing 58ºC 1 min 35 cycles
Extension 72ºC 1 min
Final Extension 72ºC 10 min
Figure 2.7: The PCR parameters.
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Figure 2.8: Schematic representation of the employed plasmids.
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The  plasmid  pQE50  (QIAGEN) allows  the  insertion  of  a  6  histidine  tag  at  the  C-
terminal  portion  of  the  protein,  in  order  to  facilitate  target  protein  purification  and 
detection  by  Western  blot  analysis.  On  the  other  hand,  using  pET15  and  pET22 
(Novagen®) it is possible to fuse the His-tag at the N- and C-terminal portion of the 
target protein, respectively, while in pET28 (Novagen®) the His-tag is inserted both at 
the N- and the C-terminus of the protein. In all the plasmids a thrombin cleavage site 
allows tag removal after protein purification.
The pGEX-4T-1 vector (Amersham Biosciences) permits to fuse the N-terminal portion 
of the target  protein to the glutathione-S-transferase (GST),  in order to  help protein 
purification;  a  thrombin  cleavage  site  is  also  placed  to  remove  GST after  protein 
purification. A second vector with GST was created, with the additional insertion of a 
His-tag at the C-terminal region of the target protein.
The amplified sequence was quantified on a 0.8% agarose TBE gel and digested with 
restriction enzymes.  The fragment was then ligated into the  NdeI/BamHI site of the 
pET15b  plasmid,  into  the  BamHI/HindIII site  of  the  pQE50,  pET22  and  pET28 
plasmids and into the BamHI/SalI site of pGEX-4T-1 plasmid.
The resulting recombinant plasmid was used to transform E. coli XL1 Blue competent 
cells  by  heat  shock  and  the  cells  were  plated  on  a  LB-agar  plate  containing  the 
appropriate antibiotic (100 μg/ml ampicillin or 50 μg/ml kanamycin);  the cells were 
then  grown  overnight  at  37ºC.  The  colonies  were  selected  by  colony  PCR  and 
subsequent  digestion  of  the  purified  plasmids;  the  vectors  were  finally  checked  by 
automated DNA sequencing.
2.2.3 Expression screening of the recombinant protein
The  pET15,  pET22,  pET28  and  pGEX-4T-1  recombinant  plasmids  were  used  to 
transform E. coli BL21 (DE3) strain cells by heat shock, while pQE50 was inserted in 
E. coli SG13009. To test protein expression, a single colony was inoculated in 3 ml of 
LB medium, grown at 37ºC adding 100 μg/ml ampicillin or 50 μg/ml kanamycin and 
then incubated at 37ºC for 4 hours and at 20ºC and 28ºC overnight after induction with 
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IPTG to a final concentration of 0.25 mM.
Centrifugation at 9,000 rpm for 10 minutes at 4ºC was performed to harvest the cells, 
that were resuspended in 2 ml of buffer A (20 mM TRIS-HCl pH 7.5, 0.5 M NaCl and 
0.02% NaN3) and subsequently disrupted by sonication. Samples were collected from 
the total lysate and, after centrifugation at 9,000 rpm for 10 minutes at 4ºC, from the 
soluble fraction and loaded onto a SDS-PAGE gel (15% polyacrylamide resolving gel 
and 4% polyacrylamide stacking gel for pQE50, pET15, pET22 and pET28, while a 
12% polyacrylamide resolving gel was used with pGEX-4T-1).
Protein  expression  was  evaluated  by  Western  blot  analysis  using  an  anti-His-tag 
monoclonal antibody for the recombinant vectors with His-tag, while for pGEX-4T-1 
only the SDS-PAGE analysis was performed.
The expression screening was repeated using another culture medium (Terrific Broth, 
TB).
Additional expression strains, such as C41(DE3), Origami, ER2566, BL21 CodonPlus 
and Rosetta (DE3), were used to test protein expression with pET15, pET22, pET28 and 
pGEX-4T-1.
2.2.4 Protein purification
Glutathione affinity chromatography
E.  coli BL21  (DE3)  cells  containing  the  plasmid  AICDA-pGEX-4T-1  were  grown 
overnight  at  37ºC  in  10  ml  of  LB  medium  containing  100  μg/ml  ampicillin,  the 
overnight culture was then transferred into 1 liter of LB medium and grown at 37ºC 
under shaking until an OD600 value of 0.8 was reached; after addition of IPTG to a final 
concentration of 0.25 mM to induce protein expression, the culture was shaken at 20ºC 
overnight. Cells were harvested by centrifugation at 8,000 rpm for 10 minutes at 4ºC 
and the pellet was then resuspended in 50 ml of buffer B (20 mM TRIS-HCl pH 7.5, 
0.15 M NaCl and 0.02% NaN3) and 1 mM DTT (dithiothreitol).
After  addition  of  0.1  mM PMSF as  protease  inhibitor,  the  cells  were  disrupted  by 
sonication; subsequently, the sample was cetrifuged at 9,000 rpm for 10 minutes at 4ºC 
to remove cell debris.
59
The  soluble  fraction  was  directly  loaded  onto  an  immobilized  glutathione  resin 
(Pharmacia), previously preequilibrated in buffer B and 1 mM DTT. After loading, the 
column was further washed with buffer B and 1 mM DTT until the U.V. absorption at 
280 nm returned to the baseline.
At the end, elution was achieved with buffer E (50 mM TRIS pH 8.0, 0.15 M NaCl, 10 
mM glutathione and 0.02% NaN3).
Immobilized Metal Ion Affinity Chromatography
The plasmid AICDA-pGEX-4T-1 with an additional insertion of a His-tag at  the C-
terminal region of the target protein was transformed into E. coli BL21 (DE3) cells. One 
liter LB culture was grown and induced according to the same procedure reported in the 
last paragraph.
The  cells  were  recovered  by  centrifugation  and  resuspended  in  buffer  A,  10  mM 
imidazole and 5 mM β mercaptoethanol, lysed by sonication and centrifuged.
Protein purification was performed using a Nickel Sepharose column (5 ml prepacked 
column,  HisTrap™ FF);  after  loading  the  soluble  fraction,  the  column  was  further 
washed until the U.V. absorption at 280 nm returned to the baseline.
Elution was achieved by applying a linear gradient ranging from 10 mM to 500 mM 
imidazole to the column.
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2.3 Results and discussion
The  human  AICDA gene  was  subcloned  into  pQE50,  pET15,  pET22  and  pET28 
plasmids; the AICDA-pQE50 plasmid was used to transform  E. coli SG13009 cells, 
while the other recombinant plasmids were used to transform E. coli BL21 (DE3) cells.
Human AICDA is a 198 amino acid chain, corresponding to a molecular weight of 24 
kDa. Three induction conditions (37ºC for 4 hours, 20ºC and 28ºC overnight) and two 
different culture media (LB and TB) were tested.
According to the subsequent Western blot analysis, the protein was not detected in the 
total  and in  the soluble fractions  in  any of the conditions  tested.  Additional  E. coli 
strains were tested, but no significant improvement in protein expression was observed; 
a different culture medium (TB) was also tested.
Figure 2.9: Western blot analysis of human AICDA in E. coli BL21 (DE3) with TB as a culture medium. 
On the left the total fractions of pET22, pET28 and pQE50 are shown in lane 1, 3 and 5 (induction at 
37ºC for 4 hours) and 2, 4 and 6 (induction at 20ºC overnight); 
the corresponding soluble fractions are shown on the right.
The human AICDA coding sequence was also inserted into pGEX-4T-1, a construct 
which allows to fuse the N-terminal target protein to GST protein; a second GST-fusion 
construct was prepared, in which a His-tag was inserted at the C-terminus of the target 
protein.
One  liter  LB  culture  of  E.  coli BL21  (DE3)  AICDA-pGEX-4T-1  was  grown  and 
induction  was  carried  out  at  20ºC  overnight;  the  cells  were  lysed  and  the  soluble 
fraction was loaded onto an immobilized glutathione resin.
In  the  SDS-PAGE  gel,  a  band  with  the  expected  molecular  weight  for  the  fusion 
construct (51 kDa) is not clearly visible in the fraction eluted with glutathione.
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Figure 2.10: SDS-PAGE analysis of AICDA after glutathione resin purification. 
T: total fraction. S: soluble fraction. FT: flow-through. W: wash. E: elution.
To check whether the protein was not expressed, not able to bind the glutathione resin or 
present in low amount in the elution, another bacterial culture was grown with the GST 
fusion construct containing an additional His-tag at the C-terminus and a Western blot 
analysis was performed.
Figure 2.11: Western blot analysis of AICDA after glutathione resin purification. 
T: total fraction. S: soluble fraction. FT: flow-through. E: elution.
The GST-AICDA-His-tag fusion protein is  present  in  both the total  and the soluble 
fraction,  but  not in the elution.  This is  due to lack of binding of the protein to the 
column; indeed the protein is entirely present in the flow-through.
The lack of binding of the fusion protein may be due to an incorrect folding of AICDA; 
according to this hypothesis, it is possible that the addition of zinc, which is known to 
interact with the active site residues of APOBEC family members, may positively affect 
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AICDA proper folding.
A new culture of E. coli BL21 (DE3) AICDA-pGEX-4T-1 was grown and, just before 
induction with ITPG, sterile ZnCl2 0.4 mM (final) was added; all the buffers used in the 
subsequent purification steps contained ZnCl2 at the same concentration.
Nevertheless, again the fusion protein is entirely present in the flow-through and no 
protein was detected in the elution fraction.
After  cell  disruption,  a  DNA binding  protein  may  bind  to  DNA in  a  non-specific 
manner; in particular, AICDA presents a high value of isoelectric point (9.50) and its 
substrate is  thought to be a single strand DNA. As a consequence,  the aspecifically 
bound nucleic acid contaminants may interfere with GST binding to the  glutathione 
resin.
In order to destroy DNA and RNA, 5 μg/ml DNase I, 5 μg/ml RNase A and 5 mM 
(final) MgCl2 were added to cells before sonication; after lysis, the cells were incubated 
for 30 minutes at 4ºC.
Additionally,  to  dissociate  the  target  protein  from  nucleic  acids,  before  the 
centrifugation to remove cell debris, 5.0 NaCl was added to the sample increasing the 
salt concentration to 1.0 M NaCl, before loading the sample onto the column.
In spite of this, the target protein did not bind to the affinity column.
Another one liter culture of E. coli BL21 (DE3) containing the plasmid AICDA-pGEX-
4T-1 with a C-terminal His-tag was grown. The fusion protein does not bind to the 
Nickel Sepharose column and it is present completely in the flow-through.
Figure 2.12: Western blot analysis of AICDA after IMAC purification. The soluble fraction (S) and the 
flow-through (F) are shown.
63
 100 kDa
 60 kDa
 45 kDa
 30 kDa
 20 kDa
 12 kDa
M S FT
The lack of protein binding to the column may occur because the His-tag is not exposed 
to the solvent, but it is buried inside the protein.
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2.4 Conclusions and prospectives
The expression of human AICDA was attempted in the prokaryotic system E. coli using 
different vectors. 
The protein was not expressed using plasmids that allow to fuse a His-tag to the target  
protein;  using the pGEX-4T-1 plasmid,  which inserts  GST at  the N-terminus of the 
protein of interest, protein expression was obtained in the soluble fraction. Nevertheless, 
the  purification  protocol  was  not  successful,  due  to  lack  of  protein  binding  to  the 
glutathione resin.
In the future,  the protein coding sequence may be cloned into different vectors that 
allow to express AICDA together with a different fusion protein, preferentially at the N-
terminus; in this way, it may be possible to obtain good expression levels of AICDA in 
the soluble fraction and then try new purification protocols.
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3. Cholesterol 7-alpha-monooxygenase
3.1 Introduction
3.1.1 Bile acids and their synthesis
Bile  acids  are  a  group  of  acidic  steroids,  synthesized  in  the  liver  and  involved  in 
emulsion and absorption of dietary fats and liposoluble vitamins [1].
They  have  24  carbon  atoms  and  their  chemical  structure  consists  of  a  saturated 
tetracyclic  hydrocarbon  perhydrocyclopentanophenanthrene  system,  called  steroid 
nucleus.
Name R1 R2 R3 R4
Cholanic acid H H H OH
Cholic acid OH OH OH OH
Chenodeoxycholic acid OH (α) OH (α) H OH
Deoxycholic acid OH H OH OH
Ursodeoxycholic acid OH (α) OH (β) H OH
Lithocholic acid OH H H OH
Glycocholate OH OH OH NHCH2COO-
Taurocholate OH OH OH NHCH2CH2SO3-
Figure 3.1: The most abundant bile acids in humans [1].
The steroid nucleus is constituted of three six-member rings (A, B and C) and a five-
member  ring  (D);  mammalian  bile  acids  have  a  5β-configuration,  that  is  A/B  ring 
junction  is  cis configuration,  with  hydroxyl  groups  at  3α,  7α and  12α.  Bile  acid 
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molecules are about 20 Å long, with an average radius of about 3.5 Å.
In human bile, these compounds are almost completely present in conjugated form with 
glycine (75%) or taurine (25%); conjugation increases water solubility of bile acids.
Bile acids are amphipathic, with a hydrophilic side (α-face) and a hydrophobic side (β-
face). The carboxylic side chain and the hydroxyl groups, that are oriented towards the 
α-side, with the exception of C-7 in UDCA (ursodeoxycholic acid), confer hydrophilic 
character to the molecule; instead, the hydrophobic methyl groups at C-18 and C-19 are 
oriented towards the β-side.
Figure 3.2: Structure of cholic acid [1].
Since they are amphipathic,  bile acids show a great surface activity and in aqueous 
solution,  when  their  concentration  reaches  a  value  above  the  critical  micellar 
concentration, they form small micelles of usually less than 10 molecules.
Bile acid synthesis
Bile  acid  formation  starts  from cholesterol,  through  two biosynthetic  pathways,  the 
“classical” and the “alternative”; in humans, bile acid synthesis is the main catabolic 
pathway of cholesterol [1, 2].
The classical pathway occurs only in the liver and leads to the synthesis of CA (cholic 
acid)  and CDCA (chenodeoxycholic  acid),  which  are  the  two primary bile  acids  in 
humans; the enzymes involved in this pathway are located in different subcellular sites, 
that  are  microsomes,  cytosol,  mitochondria  and peroxisomes.  Since the intermediate 
metabolites  are  neutral  sterols,  this  pathway  is  also  called  “neutral”  pathway;  in 
particular, the modification of the steroid nucleus occurs before the oxidative cleavage 
of its side chain.
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Figure 3.3: Bile acid biosynthesis by the classical neutral pathway [1].
The first step is catalyzed by the microsomal cholesterol 7α-hydroxylase (CP7A1) and 
consists in the hydroxylation of cholesterol at C-7; this enzyme is localized only in the 
liver and catalyzes the rate-limiting reaction of the whole pathway.
Another  microsomal  enzyme,  3β-hydroxy-Δ5-C27-steroid  dehydrogenase/isomerase 
(HSD3B7), converts the 7α-hydroxycholesterol to 7α-hydroxy-4 cholesten-3-one.
The synthesis  of CA, but  not  of  CDCA, requires the further  hydroxylation at  C-12 
position of 7α-hydroxy-4 cholesten-3-one, which is performed by another microsomal 
enzyme, sterol 12α-hydroxylase (CYP8B1).
The  two following  steps  are  carried  out  by cytosolic  enzymes,  Δ4-3-oxosteroid-5β-
reductase (AKR1D1) and 3α-hydroxysteroid dehydrogenase (AKR1C4), which catalyze 
the  reduction  of  the  double  bond,  giving  rise  to  5β-cholestan-3α,7α-diol  or  5β-
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cholestan-3α,7α,12α-triol.
The side chains of these compounds are then oxidized by the mitochondrial sterol 27-
hydroxylase  (CYP27A1),  thus  introducing  a  hydroxyl  group  to  the  C-27  position; 
subsequently,  the  resulting  precursors  are  oxidized  to  an  aldehyde  and  then  to  a 
carboxylic acid.
The  products,  3α,7α-dihydroxy-5β-cholestanoic  acid  and  3α,7α,12α-trihydroxy-5β-
cholestanoic  acid,  are  converted  to  coenzyme  A-esters  by  either  bile  acid  CoA 
synthetase  (BACS)  or  very  long  chain  acyl  CoA synthetase  (VLCS);  both  these 
enzymes are localized at the endoplasmic reticulum (ER).
The resulting precursors are then transported into peroxisomes, where their side chain is 
shortened  through  β-oxidation  by  four  enzymes,  alpha  methylacyl-CoA racemase 
(AMACR),  branched-chain  acyl  CoA  oxidase  (BCOX),  D-bifunctional  protein 
hydratase (BDP) and sterol carrier protein X (SCPx).
The final step is catalyzed by bile acid CoA: amino acid N-acyltransferase (BAAT) and 
consists in conjugation of the terminal side chain carboxylic acid with the amino acid 
glycine or taurine; this enzyme is located in peroxisomes, but a minor cytosolic fraction 
is also present.
The alternative biosynthetic pathway is  also called “acidic” pathway,  because acidic 
intermediates  are  generated;  as  a  matter  of  fact,  side  chain  oxidation  of  cholesterol 
occurs before steroid ring modification.
The first step consists in the oxidation of cholesterol to 27-hydroxycholesterol and it is 
catalyzed  by  CYP27A1;  the  following  step  leads  to  the  formation  of  7α,27-
dihydroxycholesterol  by oxysterol  7α-hydroxylase  (CYP7B1),  a  microsomal  enzyme 
present only in the acidic pathway.
Since CYP27A1 and CYP7B1 are expressed in various tissues, but only the liver has the 
required enzymes to complete bile acids biosynthesis, oxidized sterols are transported to 
the liver, where bile acids are formed. In the acidic pathway, CDCA is the main bile acid 
produced.
In  humans,  the  relative  contribution  of  the  alternative  pathway to  overall  bile  acid 
synthesis  is  low  (about  10%)  under  physiological  conditions,  but  it  may  become 
significant in patients with liver diseases.
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There are two more bile acid biosynthesis pathways, one initiated in the liver and the 
other  in  the  brain,  whose  first  reaction  is  25-hydroxylase  and  24-hydroxylase, 
respectively;  however,  the  contribution  of  these  two  pathways  to  overall  bile  acid 
production seems minor.
Biotransformation by intestinal bacteria
During their intestinal transit, bile acids are modified by intestinal bacteria. In the small 
bowel these reactions involve mainly deconjugation and hydroxyl group oxidation; bile 
acids are very efficiently absorbed in the small bowel and only a small amount (<1 g/d) 
enters the large bowel.
In  humans,  the  main  reactions  consist  of  7α-dehydroxylation,  deconjugation  and 
oxidation and epimerization of hydroxyl groups at C-3, C-7 and C-12 [1]; while 7α-
dehydroxylation is performed by a limited number of anaerobic bacteria, deconjugation 
and oxidation are carried out by a broad spectrum of anaerobes.
From CA and CDCA, dehydroxylation at  C-7 position generates the secondary bile 
acids, deoxycholic acid (DCA) and lithocholic acid (LCA).
Deconjugation consists in enzymatic hydrolysis of the C-24 N-acyl amide bond, thus 
generating unconjugated bile acids and free glycine and taurine; some unconjugated bile 
acids are then absorbed by the intestine and return through the portal vein to the liver, 
where they are reconjugated.
Oxidation  and  epimerization  of  the  3-,  7-  or  12-hydroxyl  groups  of  bile  acids  are 
catalyzed  by  bacterial  hydroxysteroid  dehydrogenases;  UDCA  is  generated  from 
epimerization of CDCA.
Dehydroxylation at C-7 position is carried out only on deconjugated bile acids.
In the intestine CA, CDCA and DCA are reabsorbed and transported back to the liver, 
while most of the LCA is lost in feces; however, a small amount of LCA is circulated 
back  to  the  liver,  where  it  is  sulfo-conjugated  at  the  3-hydroxy  position  by 
sulfotransferase (SULT2A1) and then secreted into bile. Sulfonation is a detoxification 
mechanism for hydrophobic bile acid, which are rather toxic [2].
Enterohepatic circulation
In  humans,  bile  acids  are  synthesized  in  the  liver,  secreted  into  intestine  during 
75
digestion, reabsorbed and returned to the liver through the portal circulation. About 0.2-
0.6 g of bile acids are produced daily by the human liver [1, 2].
Figure 3.4: Enterohepatic circulation of bile acids [2].
The hepatocyte canalicular bile salt export pump (BSEP) secretes conjugated bile acids 
into the bile, which is stored in the gallbladder. When their concentration increases in 
the hepatocyte, bile acids are spilled over into sinusoid blood. Bile acids present in the 
blood are absorbed in the kidneys by the renal tubules and returned to the liver through 
the systemic circulation. In the cholangiohepatic shunt, some bile acids secreted in the 
bile duct are absorbed in the cholangiocytes and then sent back to the hepatocytes.
During  digestion,  bile  acids  are  secreted  into  the  intestinal  tract  upon  gallbladder 
contraction; a small amount of bile acids is reabsorbed by passive diffusion in the upper 
intestine.
After  execution  of  their  digestive  functions,  most  bile  acids  (95%) are  captured  by 
active transport in the intestine, especially in the ileum. At the apical membrane of the 
intestinal epithelial  cells,  bile acids are recovered in an active process by the apical 
sodium dependent bile acid transporter (ASBT), while the efflux from intestinal cells 
across the basal membrane is performed by the heterodimeric organic solute transporter 
alpha and beta (OSTα-OSTβ).
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Bile acids bound to albumin reach the liver mainly through the portal blood, but also 
through  the  hepatic  artery;  subsequently,  transport  proteins  placed  at  the  sinusoidal 
membrane of hepatocytes recover  bile  acids.  The uptake of conjugated bile  acids is 
performed by the sodium taurocholate co-transport polypeptide (NTCP) in a sodium-
dependent  manner;  sinusoidal  bile  acid  uptake also occurs  in  a  sodium-independent 
process,  by  members  of  the  family  of  organic  anion  transporting  polypeptides 
(OATP1B1 and OATP1B3).
The bile acid pool (about 3 g) is recycled 4-12 times a day; bile acids lost in feces (0.2-
0.6 g) are replaced, to maintain a constant pool, by de novo synthesized bile acids in the 
liver.
Regulation of bile acids synthesis
Bile acid synthesis is mainly regulated through transcriptional modulation of CYP7A1, 
the first enzyme of the biosynthetic pathway [1 - 4].
Bile  acids  exert  a  negative  feed  back  regulation  on  the  cytochrome P450  enzymes 
CYP7A1,  CYP8B1  and  CYP27A1,  involved  in  bile  acid  biosynthesis,  through  the 
farnesoid nuclear receptor (FXR). Hydrophobic bile acids, such as CDCA, can activate 
the FXR, which in turn induces the expression of the small heterodimer partner (SHP) 
transcriptional  repressor.  In  particular,  with  a  bile  acid  as  a  ligand,  the  FXR  can 
dimerize with a nuclear hormone receptor, the retinoid X receptor (RXR); the complex 
FXR/RXR  can  induce  the  expression  of  SHP.  SHP  negatively  regulates  other 
transcription factors, the liver receptor homolog-1 (LRH-1) and the hepatocyte nuclear 
factor-4α (HNF-4α), which binds to the bile acid response elements (BARE) located in 
the promoter region of CYP7A1 and CYP8B1 and, consequently, in this way SHP can 
inhibit bile acid synthesis [5, 6].
Bile acids can inhibit CYP7A1 transcription by another FXR-dependent mechanism, 
that involves secreted fibroblast growth factor 19 (FGF-19) and its receptor (FGFR4) 
[7].
Cholesterol regulates its own catabolism to bile acids; in particular, oxysterols, oxidized 
metabolites  of  cholesterol,  activate  the  liver  X  receptor  (LXR),  which,  after 
dimerization  with  RXR,  regulates  positively  the  CYP7A1  transcription  in  rat 
hepatocytes. The LXR/RXR complex, after the binding of oxysterols to LXR, stimulates 
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the catabolic pathway of cholesterol to bile acids, thus lowering intracellular cholesterol 
levels and preventing excessive intracellular cholesterol accumulation. However, LXR 
has little or no effect on human CYP7A1, because the promoter of the human gene lacks 
an LXR response element [8].
Additionally,  CYP7A1 shows  diurnal  variations,  at  both  mRNA and  protein  levels. 
HNF-4α was proved to be required for the maintenance of CYP7A1 diurnal variation 
[9]. Also the circulating levels of FGF-19 undergo diurnal variation, in synchronicity 
with changes in CYP7A1 activity [10].
Some drugs can also influence bile acid synthesis; both phenobarbital and the antibiotic 
rifampicin  repress  CYP7A1  transcription  through  the  nuclear  receptor  constitutive 
androstane receptor (CAR) and pregnane X receptor (PXR), respectively [11, 12].
Defects in cholesterol 7α-hydroxylase
Genetic defects in the CYP7A1 gene were reported to cause a decrease in bile acid 
production through the classical pathway; however, this decrease is compensated by the 
activation of the alternative pathway. Patients show an increase in hepatic cholesterol 
content  and  adult  patients  are  usually  affected  by  LDL hypercholesterolemia  and 
cholesterol gallstones. However, patients do not usually show evidence of liver disease 
[13, 14].
3.1.2 Cytochrome P450 and cholesterol metabolism
In mammals, the most important pathways of cholesterol degradation are initiated by 
cytochrome P450 [15]; these enzymes bind a single heme group and their name derived 
from the characteristic absorption at 450 nm when reduced and in complex with CO 
[16, 17].
The cytochrome P450 family (CYP) has been found in all organisms, from bacteria to 
humans, and their members are involved in two main functional roles. First, they play a 
protective  role  against  xenobiotics  (compounds  exogenous  to  the  organism)  being 
involved in their degradation or the attachment of polar handles for solubilization in 
preparation  for  excretion;  secondly,  they  are  involved  in  the  synthesis  of  steroid 
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hormones, hydrophobic vitamin metabolism and the conversion of polyunsaturated fatty 
acids to biologically active molecules. 
In general, P450 cytochrome substrates are hydrophobic or poorly water-soluble, but 
alcohols, phenols and other organic compounds have been reported to act as substrates.
The  most  important  reaction  catalyzed by P450 cytochrome is  hydroxylation;  these 
enzymes  are  called  monooxygenases,  because  one  atom  of  molecular  oxygen  is 
incorporated into the substrate and the other into a water molecule.
To  perform  the  enzymatic  reaction  cytochrome  P450  uses  electrons  donated  from 
reduced nicotinamide adenine dinucleotide phosphate (NADPH).  Type I  cytochrome 
P450 is loosely associated to the inner mitochondrial membrane and receives electrons 
by an electron transport system composed of ferrodoxin (a 14 kDa iron-sulfur protein) 
and ferrodoxin reductase (a 54 kDa flavoprotein); type II cytochrome P450 is anchored 
to  the  inner  membrane  of  the  endoplasmic  reticulum  through  an  N-terminal 
hydrophobic segment of about 20 amino acids and receives electrons from cytochrome 
P450 oxidoreductase (an 82 kDa membrane-bound protein) [18, 19].
In  humans,  four  major  cytochrome  P45Os  use  cholesterol  as  substrate  to  initiate 
different degradation pathways.
CYP7A1 is a microsomal enzyme that catalyzes the conversion of cholesterol to 7α-
hydroxycholesterol, the first reaction of the classical pathway of bile acid synthesis; it is 
expressed only in  the liver  and it  catalyzes  the  rate-limiting  reaction  of  the overall 
pathway. Under physiological conditions, the human liver removes daily about 0.4-0.6 g 
of cholesterol.
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Figure 3.5: Cytochrome P450 involved in cholesterol catabolism [15].
CYP27A1 is a mitochondrial enzyme, expressed in many tissues and it catalyzes the 
conversion  of  cholesterol  to  27-hydroxycholesterol;  this  is  the  first  reaction  of  the 
alternative pathway of bile acid synthesis, which is initiated in extrahepatic tissues and 
eliminates daily about 20 mg of cholesterol.
In the liver this enzyme is also required in the classical pathway of bile acid synthesis 
and in the kidney it can hydroxylate vitamin D3 [20].
In  humans,  genetic  mutations  of  the  CYP27A1  gene  cause  a  disease  called 
cerebrotendinous  xanthomatosis  (CTX),  characterized  by  abnormal  deposition  of 
cholesterol and cholestan (5α-saturated analog of cholesterol) in the brain and tendons. 
The disease leads to a reduced level of bile acid synthesis, with a compensatory increase 
in  CYP7A1  activity  and  a  resulting  accumulation  of  7α-hydroxylated  bile  acid 
precursors. Oral supplementation with chenodeoxycholic acid halts CTX progression, 
by normalizing the activity of CYP7A1 [21].
CYP11A1 is a mitochondrial enzyme that metabolizes cholesterol to pregnenolone; this 
is the first reaction in steroid hormone biosynthesis and occurs in steroidogenic tissues, 
such as adrenal glands, ovaries, testis, placenta and brain [18].
About 40-50 mg of cholesterol are daily utilized to produce steroid hormones.
CYP46A1  is  a  microsomal  enzyme  expressed  in  neurons  and  it  is  responsible  for 
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cholesterol  turnover  in  the  vertebrate  central  nervous  system.  The  enzyme converts 
cholesterol  to  24-hydroxycholesterol;  in  contrast  to  cholesterol,  the  product  of  this 
enzymatic  reaction  can  cross  the  blood-brain  barrier,  enter  the  circulation  and  be 
delivered to the liver, where it undergoes further degradation [22].
This mechanism eliminates 6-7 mg of cholesterol daily.
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3.2 Materials and Methods
3.2.1 The CYP7A1 clones
The human full-lenght cDNA clone was kindly provided by Dr. D. Russell (University 
of Texas Southwestern Medical Center).
The plasmid containing the full-length cDNA clone (IMAGE ID 6790722) of zebrafish 
CYP7A1  was  purchased  from  RZPD.  E.  coli cells  harbouring  the  plasmid  vector 
pCMV-SPORT6.1  were  grown  in  3  ml  of  LB  medium  with  100  μg/ml  ampicillin 
overnight at 37ºC.
Cells were harvested by centrifugation and the plasmid vector was purified using the 
GenElute™ Plasmid Miniprep kit.
3.2.2 Subcloning of CP7A1 gene into expression vectors
The coding sequence of the human and zebrafish proteins both lacking the N-terminal 
25 amino acids were amplified by a PCR reaction using the following primers and 
parameters.
pQE50, pET28 (human):
Primer forward:
5'-GGTGGTGGATCCAGAAGGCAAACGGGTGAA-3'
Primer reverse:
5'-AATAAGCTTGGAACCACGCGGAACCAGCAAATGCTTGAATTTATA-3'
GGATCC- BamHI restriction site
AAGCTT - HindIII restriction site
GGAACCACGCGGAACCAG – thrombin cleavage site
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pET15(human):
Primer forward:
5'-GGTGGTCATATGAGAAGGCAAACGGGTGAA-3'
Primer reverse:
5'-GGTGGTGGATCCTCACAAATGCTTGAATTT-3'
CATATG - NdeI restriction site
GGATCC- BamHI restriction site
TCA - stop codon
pET22 (zebrafish):
Primer forward:
5'-GGTGGTCATATGCGCAGAAGACATCCTGCA
Primer reverse:
5'-GGTGGTCTCGAGGAGAGATTTGAGTCTGTA
CATATG - NdeI restriction site
CTCGAG - XhoI restriction site
Figure 3.6: The primers used to amplify human and zebrafish CYP7A1; 
the coding sequence is underlined.
STEP TEMPERATURE TIME
Initial Denaturation 95ºC 10 min
Denaturation 95ºC 1 min
Annealing 56ºC 1 min 35 cycles
Extension 72ºC 1 min 40 sec
Final Extension 72ºC 10 min
Figure 3.7: The PCR parameters.
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Figure 3.8: Schematic representation of the employed plasmids.
To perform protein detection and purification, the human CYP7A1 coding sequence was 
cloned into vectors that allow to insert a 6 histidine tag at the N-terminus (pET15), at 
the  C-terminus  (pQE50),  and  at  both  N-  and  C-termini  of  the  protein  (pET28).  A 
thrombin cleavage site was also inserted to remove the tag after protein purification.
The coding sequence of the zebrafish CYP7A1 was inserted into pET22, that fuses the 6 
histidine tag at the C-terminus of the target protein.
The amplified sequences were quantified on a 0.8% agarose TBE gel and digested with 
restriction enzymes; subsequently, the fragments were ligated into the  BamHI/HindIII 
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site  of  the  pQE50 and of  pET28 vectors,  into  the  NdeI/BamHI site  of  the  pET15b 
plasmid and into NdeI/XhoI site of pET22.
E. coli XL1 Blue competent cells were then transformed with the ligated plasmids by 
heat shock and the cells were plated on a LB-agar plate containing 100 μg/ml ampicillin 
or 50 μg/ml kanamycin; the cells were then grown overnight at 37ºC. The colonies were 
selected by colony PCR and then by digestion of the purified plasmids; at the end, the 
vectors were checked by automated DNA sequencing.
3.2.3 Expression screening of the recombinant protein
The recombinant plasmids were used to transform  E. coli expression strains by heat 
shock and the resulting colonies were tested for protein expression; hAICDA-pQE50 
was inserted in E. coli SG13009, BL21 (DE3) and C41 (DE3), while hAICDA-pET15, 
hAICDA-pET28  and  zAICDA-pET22  were  used  to  transform  E.  coli BL21  (DE3), 
C41(DE3), Origami, ER2566, BL21 CodonPlus and Rosetta (DE3) strains and protein 
expression was tested by Western blot analysis.
A single colony was inoculated in 3 ml of LB medium, grown at 37ºC adding 100 μg/ml 
ampicillin or 50 μg/ml kanamycin and then incubated at 37ºC for 4 hours and at 20ºC 
and 28ºC overnight after induction with 0.25 mM IPTG.
After centrifugation, the pellet was resuspended in 2 ml of buffer A (20 mM TRIS-HCl 
pH  7.5,  0.5  M  NaCl  and  0.02%  NaN3),  cells  were  disrupted  by  sonication  and 
centrifuged at 9,000 rpm for 10 minutes at 4ºC. Samples from the total lysate and from 
the soluble fraction were loaded onto an SDS-PAGE gel (12% polyacrylamide resolving 
gel and 4% polyacrylamide stacking gel). Protein expression was evaluated by Western 
blot analysis using an anti-histidine tag monoclonal antibody.
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3.3 Results and discussion
The human CYP7A1 gene was subcloned into pQE50, pET15 and pET28 plasmids, 
while the zebrafish CYP7A1 gene was inserted into pET22 vector; protein expression 
was tested  by Western blot analysis. The human CYP7A1 gene encodes a 504 amino 
acid protein with a molecular weight of 57.6 kDa, while the zebrafish CYP7A1 protein 
comprises 512 residues with a  molecular weight  of 58.7 kDa; the sequence identity 
between the two proteins is 64%.
Using the pQE50 plasmid, protein expression was observed with E. coli SG13009 only 
in the total fraction, while E. coli BL21 (DE3) and C41 (DE3) did not show any bands, 
even in the total fraction.
Figure 3.9: Western blot analysis of human CYP7A1-pEQ50 E. coli SG13009. The total and the soluble 
fractions are shown for different induction conditions: 37ºC for 4 hours (lane 1 and 2), 28ºC overnight 
(lane 3 and 4) and 20ºC overnight (lane 5 and 6).
Two bands are clearly visible in the total fractions of all the tested induction conditions; 
the band at high molecular weight shows the expected molecular weight, but has a much 
lower intensity than the other band at  low molecular weight,  which is likely due to 
protein degradation.
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With pET28, several  E. coli expression strains were tested: BL21 (DE3), C41 (DE3), 
BL21 CodonPlus, Rosetta (DE3) and ER2566.
Figure 3.10: Western blot analysis of human CYP7A1-pET28. The soluble fraction of E. coli BL21 
(DE3) are shown in lane 1 (induction at 37ºC for 4 hours), lane 2 (induction at 28ºC overnight) and lane 3 
(induction at 20ºC overnight), while the soluble fractions of E. coli C41 (DE3) are shown in lane 4 
(induction at 20ºC overnight), lane 5 (induction at 28ºC overnight) and 
lane 6 (induction at 37ºC for 4 hours).
Figure 3.11: Western blot analysis of human CYP7A1-pET28.
The soluble fractions of E. coli BL21 CodonPlus are shown in lane 1 (induction at 20ºC overnight) and 
lane 2 (induction at 37ºC for 4 hours). The fractions of E. coli Rosetta (DE3) are shown in lane 3, 4 (total 
and soluble fraction with 20ºC overnight induction) and 5 (soluble fraction with induction at 37ºC for 4 
hours). E. coli ER2566 samples are shown in lane 6, 7 (total and soluble fraction with 20ºC overnight 
induction) and 8 (soluble fraction with induction at 37ºC for 4 hours).
The best protein expression was observed with E. coli ER2566 with induction at 20ºC 
overnight; in particular, while a major band is visible at a lower molecular weight, a 
faint band at the expected molecular weight can be observed in both the total and the 
soluble fractions. 
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Target protein expression was also observed with pET15 in  E. coli BL21 (DE3) and 
C41 (DE3).
Figure 3.12: Western blot analysis of human CYP7A1-pET15. The E. coli BL21 (DE3) soluble fractions 
are shown for different induction conditions: 37ºC for 4 hours (lane 1) and 20ºC overnight (lane 2); the 
corresponding samples with E. coli C41 (DE3) strain are shown in lane 3 and 4.
A band, which corresponds to a lower molecular weight than expected, is visible in the 
soluble fractions of the tested conditions.
Finally, the zebrafish CYP7A1 gene was subcloned into the pET22 vector and protein 
expression was tested in different  E. coli expression strains and induction conditions, 
but target protein expression was not observed in any tested samples.
Figure 3.13: Western blot analysis of zebrafish CYP7A1-pET22 in E. coli BL21 (DE3). The soluble 
fractions are shown for different induction conditions: lane 1 (20ºC overnight), lane 2 (28ºC overnight) 
and lane 3 (37ºC for 4 hours); 
a total fraction is shown in lane 4, referred to induction at 37ºC for 4 hours.
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3.4 Conclusions and prospectives
Human CYP7A1 was expressed in the prokaryotic system E. coli using different vectors 
and expression conditions. Unfortunately, the protein was expressed only in the total 
form,  for  example  in  pQE50,  or  showed  a  lower  molecular  weight  than  expected, 
probably due to degradation.
The best expression conditions were obtained with E. coli ER2566 when induction was 
performed at 20ºC overnight; though most protein was degraded, a small band was still 
visible in the soluble fraction. Consequently, 1 liter LB culture was grown and induced 
and  purification  attempts  were  carried  out  by  IMAC  chromatography;  the  eluted 
fractions were cecked by SDS-PAGE gel and Western blot analysis, but no protein was 
detected. This is probably due to the very low level of expression of the target protein.
To overcome the problems encountered with protein expression in  E. coli,  different 
expression systems should be tested, such as the eukaryotic systems  Pichia pastoris, 
Saccharomyces cerevisiae and insect cells transfected with recombinant baculovirus.
A different possible  strategy consists in the study of the homologous protein from a 
different organism; the zebrafish CYP7A1 was chosen and its expression tested in  E. 
coli, but no significant improvement was obtained.
To increase protein expression, it may be useful to add δ-aminolevulinic acid (δALA), a 
heme precursor, to the bacterial culture just before IPTG induction; this compound has 
been used with success in  cytochrome P450 expression in  E. coli [23].  Presumably 
enhancing heme biosynthesis may increase protein expression and stability.
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4. Inhibitors of Methionine aminopeptidase 1 
4.1 Introduction
4.1.1 Proteolytic removal of N-terminal methionine
Protein  synthesis  starts  at  an  AUG  codon,  which  is  translated  as  the  amino  acid 
methionine. This initiator methionine is cotranslationally removed from nascent proteins 
by  methionine  amino  peptidases  (MetAPs).  Between  55  and  70  % of  proteins  are 
subject  to  the  proteolytic  removal  of  the  N-terminal  methionine.  This  process  is 
essential for the maturation of many proteins. The physical size of the second amino 
acid determines the substrate specificity of MetAPs. The N-terminal methionine will 
only be cleaved if the second residue is uncharged and small, leaving a no bulky N-
terminal  residue  such  as  Ala,  Cys,  Gly,  Pro,  Ser,  Thr  or  Val,  while  the  initiator 
methionine will be retained with remaining residues with larger side chains [1].
In prokaryotes, mitochondria and chloroplasts protein synthesis starts with a formylated 
methionine  residue.  A dedicated  enzyme,  MetRNAfMet transformylase,  adds  a  one-
carbon unit to the Met-tRNA; this reaction is thought to facilitate the recognition of 
translation factors, thus increasing the rate of protein synthesis. The formyl group is 
cleaved from most nascent proteins by peptide deformylase (PDF), thus facilitating the 
action of MetAP [2].
The enzymatic removal of N-terminal methionines occurs early in translation and is 
completed before the nascent protein is fully synthesized. Indeed, in mature proteins the 
N-terminal  amino acid  may be  buried  within  the  three-dimensional  structure  of  the 
protein or not available for enzymatic cleavage due to protein folding or location. The 
proteolytic removal of the initiator methionine is a prerequisite for the control of protein 
half-life, protein sub cellular localization and posttranslational modifications.
4.1.2 Methionine amino peptidases
While at least two genes are known in eukaryotes, most, but not all, prokaryotes have a 
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single gene encoding methionine amino peptidase.  However,  prokaryotes  with more 
than one methionine amino peptidase have been found; for example, the  Plasmodium 
falciparum genome encodes four MetAPs [3]. This family of enzymes is evolutionally 
conserved and essential, as demonstrated by knock out of the genes in both bacteria and 
yeasts [4, 5]. For example, in the budding yeast Saccharomyces cerevisiae two genes are 
present  in  the  genome  and  a  single  deletion  results  in  a  slow-growth  phenotype 
compared with the wild-type strain, but the disruption of both genes is lethal [6].
There are two classes of MetAPs. The first class (MetAP1s) occurs in Eubacteria and in 
the cytoplasm and organelles of eukaryotes, whereas the second class (MetAP2s) has 
been found in Archea and in the cytoplasm of eukaryotes. MetAP1 is further divided 
into  MetAP1a,  MetAP1b  and  MetAP1c.  MetAP1b  is  present  in  eukaryotes,  while 
MetAP1a and MetAP1c are present in prokaryotes.
Figure 4.1: Domain organization of MetAPs. Enzymes named in parentheses are 
from Escherichia coli, Mycobacterium tuberculosis and Homo sapiens [7].
The main difference between MetAP1 and MetAP2 is a 60-amino acid insertion in the 
latter. MetAP1b and MetAP1c have an N-terminal extension, whereas no such extension 
is present in MetAP1a. In MetAP1b this extension contains two zinc finger motifs and a 
connector region. Deletion of the zinc finger domain of yeast MetAP1 has no effect on 
enzymatic  activity  in  vitro,  but  determines  a  slow  growth  phenotype  in  vivo; 
consequently, the zinc finger domain is thought to be important for the function of the 
protein  in  vivo,  being  probably  involved  in  the  interaction  with  the  ribosome  [8]. 
Eukaryotic MetAP2s have an N-terminal extension not required for enzymatic activity 
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and found disorganized in  the crystal  structure of  the human enzyme [9].  MetAP2s 
present in Archea contain only catalytic and insertion domains.
4.1.3 Human MetAP1
MetAPs are metalloproteases that require divalent cations; in vitro activity has been 
observed in the presence of several divalent metals such as Fe2+, Co2+, Mn2+ and Zn2+. 
Generally  prokaryotic  MetAPs  are  thought  to  be  iron  enzymes.  However,  human 
MetAP2 seems to be a manganese enzyme, while the nature of the metal cation remains 
elusive for human MetAP1. MetAPs have five conserved amino acids involved in metal 
binding (1 His, 2 Asp and 2 Glu) and similar topology of the active site,  including 
additional conserved histidine and glutamate residues.
Figure 4.2: Sequence alignment of HsMetAP1, MtMetAP1c and EcMetAP. 
The prolines residues in the connector region are shown in blue, 
amino acids that coordinate metals are shown in red, 
residues present in S1 and S1' substrate -binding subsites are shown in yellow and green [7].
The three-dimensional structure of a truncated version (Δ 1 – 80), which lacks the zinc 
finger motifs, of human MetAP1 was determined by X – ray diffraction [7].
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Figure 4.3: Crystal structure of human tMetAP1. In red N-terminal extension, 
in green catalytic domain and in yellow cobalt ions [7]. The figure was generated using the program 
PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC). (PDB ID 
2B3K)
The  holoenzyme  contains  two  cobalt  atoms  in  the  active  site.  Apart  from  small 
differences in the conformations of the amino acids involved in interactions with metal 
cations, the apo and the holo forms are essentially identical. In the presence of an excess 
of cobalt ions, a third cobalt atom is bound to the protein, in two alternative sites; the 
holo and the trimetallo structures are essentially identical.
Three distinct Pro - X - X - Pro motifs are present in the N-terminal region of human 
MetAP1 (residues 98, 101, 104 and 107); they are thought to participate in binding to 
the ribosome.
Both the full-length and the truncated protein can be activated by Co2+,  but  neither 
protein is activated by Mn2+ or Ni2+. Only the full-length protein can be activated by a 
high concentration of Zn2+, while neither protein is activated at low concentrations of 
Zn2+.
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Figure 4.4: Activation of full-length MetAP1 and truncated MetAP1 by 
divalent cations Co2+ (filled squares) and Zn2+ open squares) [7].
The Michaelis  constant (Km) is  lower for the wild type enzyme. Truncated MetAP1 
shows a much higher value of turn over rate (Kcat). The rate constant for the enzymatic 
reaction  (Kcat/Km)  is  higher  for  the  truncated  protein,  indicating  that  tMetAP1  can 
process the substrate more efficiently than the wild type protein.
Table 4.1: Kinetic constants of truncated and full-length human MetAP1 [7].
Since the truncated protein still shows enzymatic activity, the N-terminal region of the 
protein (1- 80 residues) seems not to be essential for catalytic activity.
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4.1.4 MetAP inhibitors and their therapeutic use
Given that the N-terminal methionine excision is considered an essential mechanism 
conserved both in prokaryotes and in eukaryotes, MetAPs have been suggested to be 
good candidates for drug design; inhibitors of MetAPs are under development for a 
variety of therapies, including anti-cancer, anti-infective and anti-arthritis drugs.
Fumagillin and its anti-angiogenesis activity
Human  MetAP2  has  been  identified  as  the  primary  target  of  fumagillin,  a  potent 
inhibitor of angiogenesis; this natural compound is a sesquiterpene diepoxide, and it is 
produced by the fungus  Aspergillus fumigatus. Fumagillin and its derivatives, such as 
ovalicin and TNP-470, covalently bind and inactivate MetAP2. Human MetAP2 has 
been suggested to play an important role in endothelial cell proliferation and to mediate 
inhibition of endothelial cells by fumigillin and related analogs.
Figure 4.5: Chemical structures of fumagillin, ovalicin and TNP-470, respectively [10].
The common core structure of this class of inhibitors is a cyclohexane ring substituted 
with an epoxide at C2-C3, an epoxide-containing hydrophobic side chain at C4 and a 
methoxy  group  at  C5.  Variations  are  possible  at  C4  and  C6  positions.  Fumagillin 
contains a monoester of decatetraenedioic acid at C6, while ovalicin has a keto group at 
that position; on the other hand, TNP-470 contains a chloro-acetylcarbamoyl group at 
C6 position. The irreversible inhibition is due to the covalent bond formed by fumagillin 
with an active site histidine residue of MetAP2, which is involved in coordination of the 
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catalytic metal cation.
Figure 4.6: Interactions in the active site of human MetAP2 and fumagillin.
In yellow MetAP2, in blue inhibitor and in magenta cobalt ions [9]. (PDB ID 1BOA)
Fumagillin is covalently attached via C2 to His-231, a conserved residue in methionine 
aminopeptidase  family.  The  compound  completely  occludes  the  active  site  of  the 
enzyme, thus preventing the binding of the substrate. The C4 hydrophobic side chain 
interacts with several residues of the putative methionine binding pocket (Phe-219, His-
331, Ile-338, His-339 and Tyr-444); the extended substituent at C6 position contacts 
Leu-328, Leu-447 and Asp-376.
Fumagillin  and its  analogs  are  potent  anti-angiogenesis  agents  and they are  able  to 
prevent the vascularization and the metastasis of tumors. For example, TNP-470 was 
tested  in  clinical  trials  against  several  cancers,  including  Kaposi's  sarcoma, 
retinoblastomas, hemangiomas, renal carcinoma, breast, brain and prostate cancers [11]. 
Fumagillin and its analogs can inhibit MetAP2 with more than a million-fold higher 
affinity than MetAP1. The structure of the complex between truncated MetAP1 (Δ 1-80) 
and ovalicin, an analog of fumagillin, was determined by X-ray diffraction [12].
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Figure 4.7: Crystal structure of tMetAP1 and ovalicin [12]. (PDB ID 2GZ5)
For  both  MetAP1  and  MetAP2  the  inhibitor  makes  a  covalent  adduct  with  the 
corresponding histidine residues. The lower affinity of the compound for MetAP1 is due 
to the small size of the active site of the enzyme; indeed, several active site residues 
move “outward” in order to make room for the inhibitor. Another contributing factor is a 
different orientation of the side chain of His-310 of MetAP1 compared with His-339 in 
MetAP2. In the new position His-310 coordinates a third cobalt ion that may contribute 
to the binding of ovalicin to MetAP1 and thus may influence the affinity of this class of 
inhibitors toward the different MetAPs.
Bengamides as inhibitors of both human MetAP1 and MetAP2
Both human MetAPs were identified as the binding targets of bengamides, a class of 
compounds isolated from marine sponges; they inhibit the growth of human tumors at 
concentrations in the low nanomolar range.
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Figure 4.8: Bengamide E and two synthetic analogs (LAF153 and LAF389) [2].
Bengamides bind and inhibit both human MetAP1 and MetAP2 with similar Kd values 
for  both  enzymes.  The  structure  of  MetAp2  co-crystallized  with  LAF153  was 
determined [13]. Unlike fumagillin, which binds covalently a histidine of the active site, 
bengamides  bind  in  a  manner  that  mimics  the  expected  polipeptide  substrate.  The 
hydrophobic alkenyl  linkage of LAF153 with attached  tert-butyl  alcohol mimics the 
methionine side chain and occupies the deeply buried P1 pocket, which is thought to 
recognize the N-terminal methionine. The hydroxymethyl group of the inhibitor extends 
into  the hydrophobic P1'  pocket,  which is  thought  to  accommodate the penultimate 
residue. The caprolactam ring of the inhibitor is coordinated in the P2' region, a solvent-
exposed surface.
The central hydroxyl groups of LAF153 coordinate the two cobalt ions present in the 
active site.
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Figure 4.9: Structure of MetAP2 in complex with LAF153 [13]. (PDB ID 1QZY)
This mode of binding of bengamides is completely different from that of the previously 
known inhibitor fumagillin. Indeed, the latter forms a covalent binding with a histidine 
in the active site and makes only modest contacts with the dinuclear metal center.
Bengamides  are  not  specific  only  for  MetAP2,  but  they  have  similar  effects  as 
fumagallin in vivo, with a strong inhibitory activity in endothelial cells.
Pyridine-2-carboxylic acids as a new class of inhibitors specific for human MetAP1
The first class of inhibitors specific only for MetAP1 was that of pyridine-2-carboxylic 
acids [14].
Compounds  of  this  class  were  tested  in  vitro  against  MetAP1 and  MetAP2,  in  the 
presence of Co2+.
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Table 4.2: Structures of pyridine-2-carboxylic acids and their inhibition of MetAP1, 
MetAP2 and cell proliferation [14].
The compounds tested were able to potently inhibit MetAP1 activity with IC50 values in 
the low micromolar range, while they have no effects on MetAP2 activity. For MetAP2 
the  experiments  were  repeated  in  the  presence  of  Mn2+,  which  is  the  suggested 
physiological metal ion for this enzyme, and no inhibition was reported.
The  inhibitory effect  of  pyridine-2-carboxylic  acids  was  tested  on  cell  proliferation 
using a [3H] thymidine incorporation assay. The IC50 values obtained were in the low 
micromolar range, with both cells tested (Hela and HT-1080). The crystal structure of 
truncated MetAP1 co-crystallized with inhibitor 1 and 2 was determined [14].
104
Figure 4.10: Structure of tMetAP1 in complex with inhibitory 
compounds 1 (left) and 2 (right) [14]. (PDB ID 2NQ6 and 2NQ7)
The structure confirms the presence of two Co2+ ions in the active site of the enzyme. 
Interestingly, a third Co2+ ion was observed in the active site; this additional metal ion 
mediates  the  interaction  between  His-212 and  the  inhibitor.  The  tiazole  ring  of  the 
inhibitor is buried deeply in the active site pocket, and it is surrounded by Cys-203 and 
several hydrophobic residues (Pro-192, Tyr-195, Phe-198, Phe-309). Compounds 1 and 
2 were able to cause a significant cell delay during G2/M phase, thus suggesting that 
MetAP1 may play an important rule in this phase transition; as a consequence, MetAP1 
may be a useful target for the discovery and the development of new anticancer agents.
On the other hand, fumagillin and its analogs, which inhibit MetAP2, are able to arrest  
the cell cycle at G1/S phase.
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4.2 Materials and methods
4.2.1 Cloning of MetAP1 gene
The gene encoding for human MetAP1 lacking the first 80 amino acids (ΔMetAP1, 81-
386) was cloned into the plasmid pET28a(+) (Novagen®) with a 6-histidine tag at the N-
terminus, as reported [7]. The plasmid, pET-28a+ΔHsMetAP1, was transformed into E. 
coli BL21 (DE3) cells. Single clones were saved as glycerol stocks for inoculation.
4.2.2 Expression and purification
A glycerol stock of ΔHsMetAP1-pET-28a+ was used to inoculate 50 ml of LB medium 
containing 30 μl/ml kanamycin and shaken at 37°C overnight. 5 ml of the overnight 
culture were transferred into one liter  of LB medium with 30 μl/ml kanamycin and 
shaken at 37°C. When the O.D.600 reached 1.0, IPTG was added to a final concentration 
of  1.0  mM and  induction  was  carried  out  for  about  16  hours  at  20°C.  Cells  were 
harvested by centrifugation for 15 minutes at 5,000 rpm at 4° C and the cell pellet was 
stored at -80°C.
The cell pellet was resuspended in buffer F (50 mM HEPES pH 8.0, 0.5 M KCl, 5 mM 
imidazole,  10%  glycerol  and  0.1%  Triton  X-100).  The  cells  were  lysed  by 
microfluidization. The sample was centrifuged for 30 minutes at 12,000 rpm at 4°C to 
clear cell debris.
Ni2+ affinity  beads  (QIAGEN)  were  added  to  the  soluble  fraction,  which  was  then 
shaken for 2 hours at 4°C. Beads were then collected and washed with buffer F until the  
U.V. absorption at 280 nm returned to the baseline. The beads were washed with further 
10 ml of buffer G (50 mM HEPES pH 8.0, 0.5 M KCl and 5 mM imidazole).
The pure target protein was eluted with 10 ml of buffer H (50 mM HEPES pH 8.0, 0.5 
M KCl and 100 mM imidazole) into a 50 ml tube containing 0.2 ml of 0.5 M EDTA pH 
8.0.
The protein was dialyzed into freshly made buffer J (25 mM HEPES pH 8.0, 150 mM 
KCl and 5 mM methionine), concentrated to 3 mg/ml and stored at -80° C.
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4.2.3 Crystallization
The protein was thawed and concentrated to 6 mg/ml. Crystals of ΔHsMetAP1 were 
grown by hanging drop vapor diffusion with 1 ml reservoirs consisting of 14 – 20 % 
PEG monomethyl ether 2000, 100 mM MES pH 5.4 – 6.2. 1 μl of protein solution was 
added to the same volume of the reservoir solution. The crystals grew at 20° C, and 
appeared after 3 days. Native crystals were soaked with 1 mM inhibitor 1 and 1 mM 
CoCl2 for 1 hour and 30 minutes. Native crystals were soaked in 10 μl of reservoir 
solution for 2 days with 0.3 mM inhibitor 2 and 0.3 mM CoCl2 added.
Data collection and data processing
Data from the ΔMetAP1 crystals were collected on a FRE+ generator (Rigaku) as the X-
ray  source  with  an  R-AXIS  IV  image  plate  detector  at  the  X-ray  facility  of  the 
Department of Biophysics and Biophysical Chemistry of the Johns Hopkins University 
School of Medicine. Indexing and data reduction were carried out with HKL2000 [15].
The crystals of ΔMetAP1 are monoclinic, space group P21 and contain one molecule in 
the asymmetric unit. Data collection statistics are listed in Table 4.3.
Structure determination and refinement
The  structure  of  the  ΔMetAP1  was  determined  by  direct  refinement  using  the 
coordinates of the native enzyme (PDB ID 2B3L). The initial model was rebuilt using 
Coot  [16]  and  refined  using  Refmac5  [17].  Refinement  statistics  for  the  data  are 
summarized in Table 4.3.
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4.3 Results and discussion
Human ΔMetAP1 was cloned into the pET-28a+ plasmid and transformed in  E. coli 
BL21 (DE3) strain.  The protein was purified in a single step with Ni2+ beads; the 6-
histidine tag at the N-terminus of the protein was not cleaved.
Figure 4.11: Coomassie blue staining of 15% SDS-PAGE: M, BenchMarker, 5 μl; L, whole cell lysate, 
1/3600; S, supernatant after centrifugation, 1/3600; FT, flow-through from QIAGEN beads, 1/3600; LW, 
last wash, 17 μl; BAW, beads after wash, 1/900; E, elute, 1/1000; BAE, beads after elution; P, 
precipitation after overnight on ice and concentrating.
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The  protein  was  dialyzed  in  a  suitable  buffer,  concentrated  to  6  mg/ml  and 
crystallization trials were set up.
Figure 4.12: Microphotographs of ΔMetAP1 crystals.
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Crystal ΔMetAP1
native
ΔMetAP1
inhibitor 1
ΔMetAP1
inhibitor 2
Space group P21 P21 P21
Cell dimensions a = 47.3 Å
b = 77.2 Å
c = 47.9 Å
β = 91.7°
a = 47.3 Å
b = 77.3 Å
c = 47.8 Å 
β= 91.5°
a = 47.5 Å
b = 77.4 Å
c = 48.0 Å
β = 90.9°
Data Collection 
Statistics
X-ray Source FRE/SaturnCCD FRE/RaxisIV FRE/RaxisIV
Wavelength (Å) 1.54178 Å 1.54178 Å 1.54178 Å
Resolution (Å) 
(HighRes shell)
50-2.20
(2.28-2.20)
50-1.90
(1.97-1.90)
50-2.09 
(2.16-2.09)
Measured Reflections 53,078 74,840 71,126
Unique Reflections 16,929 24,981 20,226
I/σ 16.3 (5.5) 28.8 (3.3) 29.6 (2.8)
Completeness (%) 96.1 (80.5) 91.6 (59.7) 97.9 (86.6)
Rmerge (%) 12.2 (27.7) 5.5 (27.6) 11.7 (49.0)
Refinement
Rcryst (%) 0.175 (0.24) 0.20 (0.27)
Rfree 0.225 (0.31) 0.26 (0.32)
R.m.s deviations
Bond length (Å) 0.012 0.010
Angle (°) 1.291 1.192
Monomer in ASU 1 1
Total Atoms 2,661 2,586
Protein atoms 2,400 2,400
Water molecules 227 152
Ligand 34 34
Bfactor (MAP) Å2 29.6 41.8
Bfactor (ligand) Å2 30.9 62.0
Bfactor (H20) Å2 42.9 55.0
Table 4.3: Data collection and refinement statistics of the ΔHsMetAP1 free enzyme, and complexes with 
inhibitor 1 and 2.
The apo form of the crystal was checked to assess the absence of any compound in the 
active site pocket and it was not completely refined.
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Description of the ∆HsMetAP1 structure
The position of the two inhibitors inside the active site pocket is similar and is shown 
here.
Figure 4.13: Inhibitor 1 (left) and inhibitor 2 complexes (right) with ΔHsMetAP1.
The two inhibitors compete for the same active site and show a similar behavior in the 
binding.
Figure 4.14: Superimposition of ΔHsMetAP1 in complex with inhibitor 1 and inhibitor 2; 
the protein is shown in orange and blue, respectively.
As the two figures show, there is no change in the Cα chain, thus indicating that the 
conformation of the protein binding the two inhibitors is very similar.
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Since  the  natural  substrate  (methionine)  is  hydrophobic,  the  active  site  has  several 
hydrophobic residues.
Figure 4.15: Active site (above) and active site surface (under) of ΔHsMetAP1 
in complex with inhibitor 1 (not shown).
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6.7 Å
The inhibitors are located inside the active site pocket and completely block this cavity, 
thus avoiding substrate access. 
Figure 4.16: Active site surface of ΔHsMetAP1 in complex with inhibitor 1.
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4.4 Conclusions 
Human ΔHsMetAP1 protein has been expressed in the prokaryotic system E. coli, 
purified with a single affinity step and crystallized. The protein crystals were then 
soaked with two different inhibitors; the structure with inhibitor 1 and inhibitor 2 were 
determined to a resolution of 1.9 Å and 2.1 Å, respectively. 
The inhibitors bind to the active site pocket with a similar mechanism.
The present study will be helpful in the design of new inhibitors of this protein.
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Buffer compositions
buffer A: 20 mM TRIS-HCl pH 7.5, 0.5 M NaCl and 0.02% NaN3
buffer B: 20 mM TRIS-HCl pH 7.5, 0.15 M NaCl and 0.02% NaN3
buffer C: 20 mM TRIS-HCl pH 8.0 and 0.02% NaN3
buffer D: 20 mM TRIS-HCl pH 7.5 and 0.02% NaN3
buffer E: 50 mM TRIS pH 8.0, 0.15 M NaCl, 10 mM glutathione and 0.02% NaN3
buffer F: 50 mM HEPES pH 8.0, 0.5 M KCl, 5 mM imidazole, 10% glycerol and 0.1% 
Triton X-100
buffer G: 50 mM HEPES pH 8.0, 0.5 M KCl and 5 mM imidazole
buffer H: 50 mM HEPES pH 8.0, 0.5 M KCl and 100 mM imidazole
buffer J: 25 mM HEPES pH 8.0, 150 mM KCl and 5 mM methionine
Medium compositions
Luria-Bertani (LB) medium:
• 1% tryptone
• 0.5% yeast extract
• 0.5% NaCl
Terrific Broth (TB) medium:
• 12 g tryptone
• 24 g yeast extract
• 4 ml glycerol 
• 17 mM KH2PO4 
• 72 mM K2HPO4
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